IMAX (IMAX) 10-Q 27 Apr 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 31, 2023 shares
Document Information [Line Items]
Entity Registrant Name	IMAX Corporation
Entity Central Index Key	0000921582
Document Type	10-Q
Document Period End Date	Mar. 31, 2023
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock Shares Outstanding	54,589,933
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	Z4
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	IMAX
Security Exchange Name	NYSE
Entity File Number	001-35066
Entity Tax Identification Number	98-0140269
Entity Address, Address Line One	2525 Speakman Drive
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5K 1B1
City Area Code	(905)
Local Phone Number	403-6500
Other Address [Member]
Document Information [Line Items]
Entity Address, Address Line One	902 Broadway, Floor 20
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Country	US
Entity Address, Postal Zip Code	10010
City Area Code	(212)
Local Phone Number	821-0100

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 99,246	$ 97,401
Accounts receivable, net of allowance for credit losses	123,382	136,142
Financing receivables, net of allowance for credit losses	131,187	129,384
Variable consideration receivables, net of allowance for credit losses	47,380	44,024
Inventories	37,492	31,534
Prepaid expenses	14,296	12,343
Film assets, net of accumulated amortization	6,347	5,277
Property, plant and equipment, net of accumulated depreciation	248,279	252,896
Investment in equity securities	1,050	1,035
Other assets	15,480	15,665
Deferred income tax assets, net of valuation allowance	11,218	9,900
Goodwill	52,815	52,815
Other intangible assets, net of accumulated amortization	33,349	32,738
Total assets	821,521	821,154
Liabilities
Accounts payable	25,783	25,237
Accrued and other liabilities	113,729	117,286
Deferred revenue	73,550	70,940
Revolving credit facility borrowings, net of unamortized debt issuance costs	31,025	36,111
Convertible Notes and other borrowings, net of unamortized discounts and debt issuance costs	227,549	226,912
Deferred income tax liabilities	16,046	14,900
Total liabilities	487,682	491,386
Commitments, contingencies and guarantees (see Note 7)
Non-controlling interests
Non-controlling interests	731	722
Shareholders' equity
Capital stock common shares - no par value. Authorized - unlimited number. 54,589,933 issued and outstanding (December 31, 2022 - 54,14,614 issued and outstanding)	389,500	376,715
Other equity	170,871	185,678
Statutory surplus reserve	3,932	3,932
Accumulated deficit	(292,409)	(293,124)
Accumulated other comprehensive loss	(7,876)	(9,846)
Total shareholders' equity attributable to common shareholders	264,018	263,355
Non-controlling interests	69,090	65,691
Total shareholders' equity	333,108	329,046
Total liabilities and shareholders' equity	$ 821,521	$ 821,154

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Shareholders' equity
Common stock, par value	$ 0	$ 0
Common stock, shares issued	54,589,933	54,148,614
Common stock, shares outstanding	54,589,933	54,148,614

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues
Revenues, total	$ 86,946	$ 60,036
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	36,895	28,265
Gross margin	50,051	31,771
Selling, general and administrative expenses	34,148	30,181
Research and development	1,855	1,197
Amortization of intangible assets	1,074	1,196
Credit loss expense, net	220	7,229
Executive transition costs	1,353
Income (loss) from operations	11,401	(8,032)
Realized and unrealized investment gains	44	34
Retirement benefits non-service expense	(77)	(139)
Interest income	407	502
Interest expense	(1,767)	(1,705)
Income (loss) before taxes	10,008	(9,340)
Income tax expense	(4,885)	(2,610)
Net income (loss)	5,123	(11,950)
Less: net income attributable to non-controlling interests	(2,669)	(1,659)
Net income (loss) attributable to common shareholders	$ 2,454	$ (13,609)
Net income (loss) per share attributable to common shareholders - basic and diluted:
Net income (loss) per share attributable to common shareholders - basic	$ 0.05	$ (0.23)
Net income (loss) per share attributable to common shareholders - diluted	$ 0.04	$ (0.23)
Weighted average shares outstanding - basic	54,064	58,574
Weighted average shares outstanding - diluted	54,991	58,574
Technology Sales [Member]
Revenues
Revenues, total	$ 17,822	$ 8,976
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	7,232	5,985
Image Enhancement and Maintenance Services [Member]
Revenues
Revenues, total	47,127	36,094
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	23,085	15,743
Technology Rentals [Member]
Revenues
Revenues, total	20,058	12,661
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total	6,578	6,537
Finance Income [Member]
Revenues
Revenues, total	$ 1,939	$ 2,305

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 5,123	$ (11,950)
Other comprehensive income, before tax
Unrealized net gain from cash flow hedging instruments	134	315
Realized net loss from cash flow hedging instruments	339	29
Foreign currency translation adjustments	2,440	580
Defined benefit and postretirement benefit plans	(176)	46
Total other comprehensive income, before tax	2,737	970
Income tax expense related to other comprehensive income	(78)	(102)
Other comprehensive income, net of tax	2,659	868
Comprehensive income (loss)	7,782	(11,082)
Comprehensive income attributable to non-controlling interests	(3,358)	(1,826)
Comprehensive income (loss) attributable to common shareholders	$ 4,424	$ (12,908)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating Activities
Net income (loss)	$ 5,123	$ (11,950)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:
Depreciation and amortization	13,320	12,741
Amortization of deferred financing costs	625	1,023
Credit loss expense, net	220	7,229
Write-downs	304	381
Deferred income tax benefit	(193)	(109)
Share-based and other non-cash compensation	5,135	6,189
Unrealized foreign currency exchange (gain) loss	(78)	58
Realized and unrealized investment gains	(44)	(34)
Changes in assets and liabilities:
Accounts receivable	12,374	(2,654)
Inventories	(5,946)	(534)
Film assets	(3,884)	(5,107)
Deferred revenue	2,606	(830)
Changes in other operating assets and liabilities	(8,344)	(10,186)
Net cash provided by (used in) operating activities	21,218	(3,783)
Investing Activities
Purchase of property, plant and equipment	(364)	(728)
Investment in equipment for joint revenue sharing arrangements	(2,157)	(4,587)
Interest in film classified as a financial instrument		(4,731)
Acquisition of other intangible assets	(1,760)	(551)
Net cash used in investing activities	(4,281)	(10,597)
Financing Activities
Revolving credit facility borrowings	25,717
Repayments of revolving credit facility borrowings	(31,180)
Credit facility amendment fees paid		(1,783)
Other borrowings	315
Repurchase of common shares	(3,656)	(6,272)
Taxes withheld and paid on employee stock awards vested	(6,233)	(3,136)
Net cash used in financing activities	(15,037)	(13,035)
Effects of exchange rate changes on cash	(55)	4
Increase (decrease) in cash and cash equivalents during period	1,845	(27,411)
Cash and cash equivalents, beginning of period	97,401	189,711
Cash and cash equivalents, end of period	$ 99,246	162,300
IMAX China
Financing Activities
Repurchase of common shares		$ (1,844)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Capital Stock [Member]	Other Equity [Member]	Statutory Surplus Reserve [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-controlling Interests [Member]
Balance, beginning of period at Dec. 31, 2021		$ 409,979	$ 174,620	$ 3,932	$ (234,975)	$ 2,527
Movement of Shareholders' Equity
Amortization of share-based payment expense - stock options			231
Amortization of share-based payment expense - restricted share units			4,350
Amortization of share-based payment expense - performance stock units			1,854
Common shares repurchased and retired		(3,662)			(2,610)
Restricted share units vested		9,045	(12,600)
Change in ownership interest related to IMAX China common share repurchases			(543)				$ (1,301)
Net income (loss) attributable to common shareholders	$ (13,609)				(13,609)
Net income attributable to non-controlling interests	1,659						1,656
Other comprehensive income, net of tax	868					701
Other comprehensive (loss) income, net of tax							167
Share-based compensation attributable to non-controlling interests							28
Balance, end of period at Mar. 31, 2022		415,362	167,912	3,932	(251,194)	3,228
Balance, beginning of period at Dec. 31, 2021							73,531
Balance, end of period at Mar. 31, 2022							74,081
Movement of Shareholders' Equity
Total shareholders' equity	413,321
Total shareholders' equity	329,046
Balance, beginning of period at Dec. 31, 2022	263,355	376,715	185,678	3,932	(293,124)	(9,846)
Movement of Shareholders' Equity
Amortization of share-based payment expense - stock options			91
Amortization of share-based payment expense - restricted share units			3,314
Amortization of share-based payment expense - performance stock units			1,021
Common shares repurchased and retired		109			(1,739)
Restricted share units vested		12,676	(19,233)
Net income (loss) attributable to common shareholders	2,454				2,454
Net income attributable to non-controlling interests	2,669						2,660
Other comprehensive income, net of tax	2,659					1,970
Other comprehensive (loss) income, net of tax							689
Share-based compensation attributable to non-controlling interests							50
Balance, end of period at Mar. 31, 2023	264,018	$ 389,500	$ 170,871	$ 3,932	$ (292,409)	$ (7,876)
Balance, beginning of period at Dec. 31, 2022	65,691						65,691
Balance, end of period at Mar. 31, 2023	69,090						$ 69,090
Movement of Shareholders' Equity
Total shareholders' equity	$ 333,108

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation Accounting Principles IMAX Corporation, together with its consolidated subsidiaries (the “Company” or “IMAX”), prepares its financial statements in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the Company’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments of a normal recurring nature that are necessary for a fair statement of the results for the interim periods presented. The Condensed Consolidated Balance Sheet at December 31, 2022 was derived from the Company’s audited annual Consolidated Financial Statements, but does not contain all of the footnote disclosures included in the annual financial statements. The interim results presented in the Company’s Condensed Consolidated Statements of Operations are not necessarily indicative of results for a full year. These Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements included in the Company’s 2022 Annual Report on Form 10-K (the “2022 Form 10-K”), which should be consulted for a summary of the significant accounting policies utilized by the Company. The Condensed Consolidated Financial Statements are prepared following the same accounting policies disclosed in the 2022 Form 10-K. As disclosed in Note 13 to the Condensed Consolidated Financial Statements, in the first quarter of 2023, the Company revised its reportable segments. Principles of Consolidation These Condensed Consolidated Financial Statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions have been eliminated. The Company has evaluated its various variable interests to determine whether they are VIEs as required by U.S. GAAP. The Company has interests in ten film production companies, which have been identified as VIEs. The Company is the primary beneficiary of and consolidates five of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant. The majority of the assets relating to these production companies are held by the IMAX Original Film Fund (the “Original Film Fund”) as described in Note 17 (b). The Company does not consolidate the other five film production companies because it does not have the power to direct their activities and it does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Condensed Consolidated Financial Statements. A loss in the value of an equity method investment that is other than temporary is recognized as a charge in the Condensed Consolidated Statement of Operations. As of March 31, 2023 and December 31, 2022, total assets and liabilities of the Company’s consolidated VIEs are as follows: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Total assets $ 1,537 $ 1,523 Total liabilities $ 248 $ 248 Estimates and Assumptions In preparing the Company’s Condensed Consolidated Financial Statements, management makes judgments in applying various accounting policies. The areas of policy judgment are consistent with those reported in Note 3(b) of the Company’s audited Consolidated Financial Statements included in its 2022 Form 10-K. Management also considers that its determination of operating and reporting segments represents an area of judgment, and has made this conclusion on the basis of what comprises the discrete financial information produced, but not provided to or used by its Chief Operating Decision Maker (“CODM”) to carry out this function. In addition, management makes assumptions about the Company’s future operating results and cash flows in deriving critical accounting estimates used in preparing the Condensed Consolidated Financial Statements. The significant estimates made by management include, but are not limited to: (i) the allocation of the transaction price in an IMAX System arrangement to distinct performance obligations; (ii) the amount of variable consideration to be earned on sales of IMAX Systems based on projections of future box office performance; (iii) expected credit losses on accounts receivable, financing receivables, and variable consideration receivables; (iv) provisions for the write-down of excess and obsolete inventory; (v) the fair values of the reporting units used in assessing the recoverability of goodwill; (vi) the cash flow projections used in testing the recoverability of long-lived assets such as the system equipment supporting joint revenue sharing arrangements; (vii) the economic lives of the system equipment supporting joint revenue sharing arrangements; (viii) the useful lives of intangible assets; (ix) the ultimate revenue forecasts used to test the recoverability of film assets; (x) the discount rates used to determine the present value of financing receivables and lease liabilities, as well as to determine the fair values of the Company’s reporting units for the purpose of assessing the recoverability of goodwill; (xi) pension plan assumptions; (xii) estimates related to the fair value and projected vesting of share-based payment awards; (xiii) the valuation of deferred income tax assets; and (xiv) reserves related to uncertain tax positions.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	3 Months Ended
	Mar. 31, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]
Recently Issued Accounting Standards	2. Recently Issued Accounting Standards Adoption of New Accounting Policies In March 2022, the FASB issued ASU No. 2022-02, “2022-02: Financial Instruments — Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures” (“ASU 2022-02” ). ASU 2022-02 amends and eliminates the accounting guidance for Troubled Debt Restructurings by creditors, while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty and requires for public business entities, to disclose current-period gross write offs by year of origination for financing receivables and net investments in leases. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2022-02 for the period ended March 31, 2023. The adoption of ASU 2022-02 did no t have a material impact on the Company's Condensed Consolidated Financial Statements. In September 2022, the FASB issued ASU No. 2022-04, “2022-04: Liabilities — Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations” (“ASU 2022-04” ). ASU 2022-04 requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2022-04 for the period ended March 31, 2023 . The adoption of ASU 2022-04 did no t have a material impact on the Company's Condensed Consolidated Financial Statements. Recently Issued FASB Accounting Standard Codification Updates Not Yet Adopted The Company considers the applicability and impact of all FASB ASUs that are recently issued, but not yet effective. ASUs that are not noted above were assessed and determined to be not applicable or not significant to the Company’s Condensed Consolidated Financial Statements for the period ended March 31, 2023 .

Receivables

Receivables	3 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
Receivables	3. Receivables The ability of the Company to collect its receivables is principally dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators, or other customers, may experience financial difficulties that could result in them being unable to fulfill their payment obligations to the Company. In order to mitigate the credit risk associated with its receivables, management performs an initial credit evaluation prior to entering into an arrangement with a customer and then regularly monitors the credit quality of each customer through an analysis of collections history and aging. This monitoring process includes meetings on at least a monthly basis to identify credit concerns and potential changes in credit quality classification. A customer may improve their credit quality classification once a substantial payment is made on an overdue balance or when the customer has agreed to a payment plan and payments have commenced in accordance with that plan. Changes in credit quality classification are dependent upon management approval. The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are received on a regular basis. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears, and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category, but are not in as good condition as the receivables in the Credit Watch category. In certain situations, a theater operator may be placed on nonaccrual status and all revenue recognition related to the theater may be suspended, including the accretion of Finance Income for Financing Receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are suspended, including the accretion of Finance Income for Financing Receivables. During the period when the accretion of Finance Income is suspended for Financing Receivables, any payments received from a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a reversal of the provision is recorded to the extent of the residual cash received. Once the collectability issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of Finance Income. When a customer’s aging exceeds 90 days, the Company’s policy is to perform an enhanced review to assess collectability of the theater’s past due accounts. The over 90 days past due category may be an indicator of potential impairment as up to 90 days outstanding is considered to be a reasonable time to resolve any issues. The Company develops an estimate of expected credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates, which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after considering management’s internal credit quality classifications. Additional credit loss provisions are also recorded taking into account macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management. Commencing in March 2022, in response to numerous sanctions imposed by the United States, Canada and the European Union on companies transacting in Russia and Belarus resulting from ongoing conflict between Russia and Ukraine, the Company suspended its operations in Russia and Belarus. In the first quarter of 2022, the Company recorded provisions for potential credit losses against substantially all of its receivables in Russia due to uncertainties associated with the ongoing conflict and resulting sanctions. These receivables relate to existing sale agreements as the Company is not party to any joint revenue sharing arrangements in these countries. In addition, beginning in the first quarter of 2022, exhibitors in Russia, Ukraine, and Belarus were placed on nonaccrual status for maintenance revenue and finance income. As of March 31, 2023, all IMAX Systems in Ukraine have reopened. The Company continues to closely monitor the evolving impacts of this conflict (including the sanctions imposed by the United States, Canada and the European Union) and its effects on the global economy and the Company. On September 7, 2022, Cineworld, the parent company of Regal, and certain of its subsidiaries and Regal CineMedia Holdings, LLC, filed petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in the Southern District of Texas. The Company had an unsecured pre-petition claim of $ 11.4 million related to receivables from the entities included in the reorganization proceedings. On October 21, 2022, the Company was ratified by the bankruptcy court as a critical vendor of Cineworld, allowing the Company to collect pre-petition amounts owed to it by Cineworld, and requiring Cineworld to stay current on the Company’s post-petition receivables. On November 8, 2022, IMAX Corporation entered into a trade agreement with Cineworld (the “Trade Agreement”), pursuant to which Cineworld affirmed its pre-petition obligations to the Company and its post-petition obligations to the Company during the Chapter 11 proceedings, the amount of the receivables owed to the Company and agreed to a payment plan under which all amounts due will be settled over the period from November 9, 2022 to April 12, 2023. As of April 17, 2023, the Company had received all of the payments due from Cineworld in accordance with the terms of the Trade Agreement with respect to the pre-petition obligations. Based on its evaluation of its contracts with Cineworld, its assessment of the reorganization and its discussions with Cineworld to date, the Company has determined that no additional provision for expected credit losses is required. The Company also does not expect to see a material impact on its IMAX network with Cineworld resulting from this reorganization. There can, however, be no guarantees as to the ultimate outcome of a Chapter 11 proceeding. Management’s judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. As a result, the Company’s judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect. The impacts of inflation, and rising interest rates may impact future credit losses. The Company will continue to monitor economic trends and conditions and portfolio performance and adjust its allowance for credit loss accordingly. Accounts Receivable Accounts receivable principally includes amounts currently due to the Company under IMAX System sale and sales-type lease arrangements, contingent fees owed by theater operators as a result of box office performance, and fees for maintenance services. Accounts receivable also includes amounts due to the Company from movie studios and other content creators principally for digitally remastering films into IMAX formats, as well as for film distribution and post-production services. The following tables summarize the activity in the allowance for credit losses related to Accounts Receivable for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 (In thousands of U.S. Dollars) Theater Studios Other Total Beginning balance $ 11,144 $ 1,699 $ 1,276 $ 14,119 Current period (reversal) provision, net ( 265 ) 3 21 ( 241 ) Write-offs ( 115 ) — — ( 115 ) Foreign exchange 60 5 — 65 Ending balance $ 10,824 $ 1,707 $ 1,297 $ 13,828 Three Months Ended March 31, 2022 (In thousands of U.S. Dollars) Theater Studios Other Total Beginning balance $ 8,867 $ 1,994 $ 1,085 $ 11,946 Current period provision, net 1,981 3 273 2,257 Write-offs — — — — Foreign exchange ( 17 ) ( 2 ) — ( 19 ) Ending balance $ 10,831 $ 1,995 $ 1,358 $ 14,184 For the three months ended March 31, 2023 , the Company’s allowance for current expected credit losses related to Accounts Receivable decreased by $ 0.4 million. For the three months ended March 31, 2022 , the Company’s allowance for current expected credit losses related to Accounts Receivable increased by $ 2.2 million, principally due to reserves established against its receivables in Russia due to uncertainties associated with the ongoing Russia-Ukraine conflict, partially offset by the reversal of provisions associated with the COVID-19 pandemic. Financing Receivables Financing receivables are due from theater operators and consist of the Company’s net investment in sales-type leases and receivables associated with financed sales of IMAX Systems. As of March 31, 2023 and December 31, 2022, financing receivables consist of the following: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Net investment in leases Gross minimum payments due under sales-type leases $ 32,097 $ 29,727 Unearned finance income ( 557 ) ( 619 ) Present value of minimum payments due under sales-type leases 31,540 29,108 Allowance for credit losses ( 778 ) ( 776 ) Net investment in leases 30,762 28,332 Financed sales receivables Gross minimum payments due under financed sales 141,119 141,337 Unearned finance income ( 29,161 ) ( 29,340 ) Present value of minimum payments due under financed sales 111,958 111,997 Allowance for credit losses ( 11,533 ) ( 10,945 ) Net financed sales receivables 100,425 101,052 Total financing receivables $ 131,187 $ 129,384 Net financed sales receivables due within one year $ 33,721 $ 32,366 Net financed sales receivables due after one year 66,704 68,686 Total financed sales receivables $ 100,425 $ 101,052 As of March 31, 2023 and December 31, 2022, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: March 31, December 31, 2023 2022 Weighted-average remaining lease term (in years) Sales-type lease arrangements 8.9 9.0 Weighted-average interest rate Sales-type lease arrangements 8.25 % 8.23 % Financed sales receivables 8.85 % 8.79 % The tables below provide information on the Company’s net investment in leases by credit quality indicator as of March 31, 2023 and December 31, 2022. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of March 31, 2023 2023 2022 2021 2020 2019 Prior Total Net investment in leases: Credit quality classification: In good standing $ 2,200 $ 4,141 $ 7,017 $ 2,544 $ 2,020 $ 1,020 $ 18,942 Credit Watch — — — — — — — Pre-approved transactions — — 3,112 1,179 5,423 2,483 12,197 Transactions suspended — — — — — 401 401 Total net investment in leases $ 2,200 $ 4,141 $ 10,129 $ 3,723 $ 7,443 $ 3,904 $ 31,540 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2022 2022 2021 2020 2019 2018 Prior Total Net investment in leases: Credit quality classification: In good standing $ 4,148 $ 6,969 $ 2,494 $ 1,977 $ — $ 1,016 $ 16,604 Credit Watch — — — — — — — Pre-approved transactions — 3,089 1,162 5,401 2,451 — 12,103 Transactions suspended — — — — — 401 401 Total net investment in leases $ 4,148 $ 10,058 $ 3,656 $ 7,378 $ 2,451 $ 1,417 $ 29,108 The tables below provide information on the Company’s financed sale receivables by credit quality indicator as of March 31, 2023 and December 31, 2022. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of March 31, 2023 2023 2022 2021 2020 2019 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 2,163 $ 9,830 $ 8,617 $ 6,381 $ 8,149 $ 45,647 $ 80,787 Credit Watch — 1 — — — 943 944 Pre-approved transactions — — 2,377 1,162 1,590 13,220 18,349 Transactions suspended — 272 795 142 1,256 9,413 11,878 Total financed sales receivables $ 2,163 $ 10,103 $ 11,789 $ 7,685 $ 10,995 $ 69,223 $ 111,958 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2022 2022 2021 2020 2019 2018 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 10,252 $ 8,643 $ 6,280 $ 8,541 $ 9,854 $ 39,912 $ 83,482 Credit Watch — — — — — 1,152 1,152 Pre-approved transactions — 2,318 1,399 1,134 1,449 9,243 15,543 Transactions suspended 272 664 142 1,269 1,197 8,276 11,820 Total financed sales receivables $ 10,524 $ 11,625 $ 7,821 $ 10,944 $ 12,500 $ 58,583 $ 111,997 The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as of March 31, 2023 and December 31, 2022: As of March 31, 2023 (In thousands of U.S. Dollars) Accrued 30-89 90+ Billed Unbilled Recorded Allowance Net Net investment in leases $ 235 $ 433 $ 2,892 $ 3,560 $ 27,980 $ 31,540 $ ( 778 ) $ 30,762 Financed sales receivables 1,352 3,190 13,131 17,673 94,285 $ 111,958 ( 11,533 ) 100,425 Total $ 1,587 $ 3,623 $ 16,023 $ 21,233 $ 122,265 $ 143,498 $ ( 12,311 ) $ 131,187 As of December 31, 2022 (In thousands of U.S. Dollars) Accrued 30-89 90+ Billed Unbilled Recorded Allowance Net Net investment in leases $ 237 $ 216 $ 2,593 $ 3,046 $ 26,062 $ 29,108 $ ( 776 ) $ 28,332 Financed sales receivables 2,269 1,307 12,793 16,369 95,628 111,997 ( 10,945 ) 101,052 Total $ 2,506 $ 1,523 $ 15,386 $ 19,415 $ 121,690 $ 141,105 $ ( 11,721 ) $ 129,384 The following tables provide information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as of March 31, 2023 and December 31, 2022. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. As of March 31, 2023 (In thousands of U.S. Dollars) Accrued 30-89 Days 90+ Days Billed Unbilled Allowance Net Net investment in leases $ 220 $ 387 $ 2,892 $ 3,499 $ 18,286 $ ( 228 ) $ 21,557 Financed sales receivables 940 2,356 10,445 13,741 42,785 ( 1,460 ) 55,066 Total $ 1,160 $ 2,743 $ 13,337 $ 17,240 $ 61,071 $ ( 1,688 ) $ 76,623 As of December 31, 2022 (In thousands of U.S. Dollars) Accrued 30-89 Days 90+ Days Billed Unbilled Allowance Net Net investment in leases $ 190 $ 181 $ 2,593 $ 2,964 $ 17,070 $ ( 230 ) $ 19,804 Financed sales receivables 1,550 1,115 10,814 13,479 43,172 ( 1,587 ) 55,064 Total $ 1,740 $ 1,296 $ 13,407 $ 16,443 $ 60,242 $ ( 1,817 ) $ 74,868 The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as of March 31, 2023 and December 31, 2022: As of March 31, 2023 As of December 31, 2022 (In thousands of U.S. Dollars) Recorded Allowance Net Recorded Allowance Net Net investment in leases $ 401 $ ( 401 ) $ — $ 401 $ ( 401 ) $ — Net financed sales receivables 20,461 ( 7,599 ) 12,862 27,364 ( 9,589 ) 17,775 Total $ 20,862 $ ( 8,000 ) $ 12,862 $ 27,765 $ ( 9,990 ) $ 17,775 For the three months ended March 31, 2023 , the Company recognized less than $ 0.1 million ( 2022 — less than $ 0.1 million ) in Finance Income related to the net investment in leases with billed amounts past due. For the three months ended March 31, 2023 and 2022 , the Company did no t recognize Finance Income related to the net investment in leases on nonaccrual status. For the three months ended March 31, 2023, the Company recognized $ 0.8 million (2022 — $ 0.7 million ) in Finance Income related to the financed sale receivables with billed amounts past due. For the three months ended March 31, 2023, the Company recognized $ 0.1 million (2022 — $ 0.2 million ) in Finance Income related to the financed sales receivables in nonaccrual status. The following tables summarize the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 Net Investment Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 776 $ 10,945 Current period (reversal) provision, net ( 2 ) 549 Write-offs — — Foreign exchange 4 39 Ending balance $ 778 $ 11,533 Three Months Ended March 31, 2022 Net Investment Net Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 798 $ 5,414 Current period (reversal) provision, net ( 93 ) 5,708 Write-offs — — Foreign exchange 1 13 Ending balance $ 706 $ 11,135 For the three months ended March 31, 2022 , the Company’s allowance for current expected credit losses related to its net investment in leases and financed sale receivables increased by $ 5.6 million, principally due to reserves established against its receivables in Russia due to uncertainties associated with the ongoing Russia-Ukraine conflict and resulting sanctions, partially offset by the reversal of provisions associated with the COVID-19 pandemic as the outlook for the theatrical exhibition industry in Domestic and Rest of World markets improved. Variable Consideration Receivables In sale arrangements, variable consideration may become due to the Company from theater operators if certain annual minimum box office receipt thresholds are exceeded. Such variable consideration is recorded as revenue in the period when the sale is recognized and adjusted in future periods based on actual results and changes in estimates. Variable consideration is only recognized to the extent the Company believes there is not a risk of significant revenue reversal. The following table summarizes the activity in the Allowance for Credit Losses related to Variable Consideration Receivables for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 2022 (In thousands of U.S. Dollars) Theater Theater Beginning balance $ 610 $ 1,082 Current period reversal, net ( 86 ) ( 643 ) Foreign exchange 2 — Ending balance $ 526 $ 439 For the three months ended March 31, 2023 , the Company’s allowance for current expected credit losses related to Variable Consideration Receivables decreased by $ 0.1 million. For the three months ended March 31, 2022, the Company’s allowance for current expected credit losses related to Variable Consideration Receivables decreased by $ 0.6 million. This decrease is principally due to the reversal of provisions associated with the COVID-19 pandemic as the outlook for the theatrical exhibition industry in Domestic and Rest of World markets improved .

Lease Arrangements

Lease Arrangements	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Lease Arrangements	4. Lease Arrangements (a) IMAX Corporation as a Lessee The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term. Most of the Company’s leases include one or more options to renew, with renewal terms that can extend the lease term from one to five years or more. The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs and its level of investment in leasehold improvements, among other factors. The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property. None of the Company’s leases include options to purchase the leased property. The depreciable lives of right-of-use assets and related leasehold improvements are limited by the expected lease term. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed. In the second quarter of 2022, the Company entered into a finance lease arrangement involving equipment used to facilitate the delivery of live events to certain IMAX locations. The lease arrangement includes an option for the Company to purchase the equipment at the end of the lease term that is reasonably certain to be exercised. The resulting right-of-use assets are being depreciated from the lease commencement dates over the useful life of the underlying equipment. The incremental borrowing rate used in the calculation of the lease liabilities is based on the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term. For the three months ended March 31, 2023 and 2022, the components of lease expense recorded within Selling, General and Administrative Expenses are as follows: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Operating lease cost: Amortization of operating lease assets $ 151 $ 693 Interest on operating lease liabilities 724 215 Short-term and variable lease costs 204 160 Finance lease cost: Amortization of finance lease assets 100 N/A Interest on finance lease liabilities 14 N/A Total lease cost $ 1,193 $ 1,068 For the three months ended March 31, 2023 and 2022, supplemental cash and non-cash information related to leases is as follows: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating leases $ 971 $ 945 Finance leases $ — N/A Supplemental disclosure of noncash leasing activities: Right-of-use assets obtained in exchange for operating lease obligations $ 228 $ 217 Right-of-use assets obtained in exchange for finance lease obligations $ — N/A As of March 31, 2023 and December 31, 2022, supplemental balance sheet information related to leases is as follows: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Assets Balance Sheet Location Operating lease right-of-use assets Property, plant and equipment $ 11,888 $ 12,341 Finance lease right-of-use assets Property, plant and equipment $ 1,776 $ 1,876 Liabilities Balance Sheet Location Operating lease liabilities Accrued and other liabilities $ 14,140 $ 14,461 Finance lease liabilities (1) Accrued and other liabilities $ 967 $ 1,011 (1) Recorded net of a $ 0.9 million upfront payment made upon execution of the finance lease arrangement. As of March 31, 2023 and December 31, 2022, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s leases are as follows: March 31, December 31, 2023 2022 Operating leases: Weighted-average remaining lease term (years) 5.8 6.0 Weighted-average discount rate 5.91 % 5.90 % Finance leases: Weighted-average remaining lease term (years) 4.4 4.7 Weighted-average discount rate 6.00 % 6.00 % As of March 31, 2023, the maturities of the Company’s operating and finance lease liabilities are as follows: (In thousands of U.S. Dollars) Operating Leases Finance Leases 2023 (nine months remaining) $ 2,699 $ 508 2024 3,049 508 2025 2,457 — 2026 2,069 — 2027 2,093 — Thereafter 4,354 — Total lease payments $ 16,721 $ 1,016 Less: interest expense ( 2,581 ) ( 49 ) Present value of lease liabilities $ 14,140 $ 967 (b) IMAX Corporation as a Lessor The Company provides IMAX Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system. The customer’s rights under the Company’s sales-type lease arrangements are described in Note 3(o) of the Company’s audited Consolidated Financial Statements included in its 2022 Form 10-K. Under the Company’s sales-type lease arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s lease portfolio terms are typically non-cancellable for 10 years or longer with renewal provisions from inception. The Company’s sales-type lease arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty generally after the first year of the lease until the end of the lease term. The customer is responsible for obtaining insurance coverage for the IMAX System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX System is returned to the Company. The Company also provides IMAX Systems to customers through joint revenue sharing arrangements. Under the traditional form of these arrangements, in exchange for providing the IMAX System under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than requiring the customer to pay a fixed upfront fee or annual minimum payments. Under certain other joint revenue sharing arrangements, known as hybrid arrangements, the customer is responsible for making fixed upfront payments prior to the delivery and installation of the IMAX System. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to the IMAX System under a joint revenue sharing arrangement generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX System is returned to the Company. The following lease payments are expected to be received by the Company for its sales-type leases and joint revenue sharing arrangements in each of the next five years and thereafter following the March 31, 2023 balance sheet date: Sales-Type Joint Revenue (In thousands of U.S. Dollars) Leases Sharing Arrangements 2023 (nine months remaining) $ 2,260 $ 130 2024 3,519 69 2025 3,248 27 2026 3,163 — 2027 3,018 — Thereafter 16,889 — Total $ 32,097 $ 226

Inventories

Inventories	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventories	5. Inventories As of March 31, 2023 and December 31, 2022, Inventories consist of the following: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Raw materials $ 29,554 $ 25,365 Work-in-process 2,220 2,034 Finished goods 5,718 4,135 $ 37,492 $ 31,534 As of March 31, 2023, Inventories include finished goods of $ 5.3 million (December 31, 2022 — $ 3.5 million ) for which title had passed to the customer, but the criteria for revenue recognition were not met as of the balance sheet date. During the three months ended March 31, 2023 and 2022 , the Company had recorded write-downs of less than $ 0.1 million in Costs and Expenses Applicable to Revenues ― Technology Sales .

Borrowings

Borrowings	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Borrowings	6. Borrowings (a) Revolving Credit Facility Borrowings, Net As of March 31, 2023 and December 31, 2022, Revolving Credit Facility Borrowings, Net includes the following: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Wells Fargo Credit Facility borrowings $ 20,000 $ 25,000 HSBC China Facility borrowings 12,165 12,496 Bank of China Facility borrowings 379 374 Unamortized debt issuance costs ( 1,519 ) ( 1,759 ) Revolving Credit Facility Borrowings, net $ 31,025 $ 36,111 Wells Fargo Credit Agreement On March 25, 2022, the Company entered into a Sixth Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as agent (the “Agent”), and a syndicate of lenders party thereto (the “Credit Agreement”), which extended the maturity date of the credit facility under the Credit Agreement (the “Credit Facility”) from June 28, 2023 to March 25, 2027 . The Company’s obligations under the Credit Agreement are guaranteed by certain of the Company’s subsidiaries (the “Guarantors”), and are secured by first-priority security interests in substantially all of the assets of the Company and the Guarantors. The Credit Agreement has a revolving borrowing capacity of $ 300.0 million, and contains an uncommitted accordion feature allowing the Company to further increase its borrowing capacity by the greater of $ 140.0 million, for a total of $ 440.0 million, or by the Company’s EBITDA for the sum of the four most recently ended fiscal quarters, subject to certain conditions, depending on the mix of revolving loans and/or term loans under the incremental facility and subject to conditions set forth in the Credit Agreement. The Credit Facility requires that the Company maintain a maximum Senior Secured Net Leverage Ratio (as defined in the Credit Agreement) of no greater than 3.25 :1.00, on the last day of each Fiscal Quarter. The Senior Secured Net Leverage Ratio is the ratio of Total Debt (as defined in the Credit Agreement), secured by liens, net of unrestricted cash and cash equivalents held outside of the People's Republic of China (“the PRC”) to a maximum of $ 75.0 million, relative to Adjusted EBITDA per Credit Facility for the four prior quarters. The Senior Secured Net Leverage Ratio is calculated using Adjusted EBITDA per Credit Facility determined on a trailing twelve-month basis. The Company was in compliance with this requirement as of March 31, 2023 as the Senior Secured Net Leverage Ratio was 0.00 :1.00. Loans under the Credit Facility bear interest, at the Company’s option, at (i) Term Secure Overnight Financing Rate (“SOFR”), Eurocurrency Rate or Canadian Dollar Offered Rate (“CDOR”) plus a margin ranging from 1.00 % to 1.75 % per annum; or (ii) the U.S. base rate or the Canadian prime rate plus a margin ranging from 0.25 % to 1.00 % per annum, in each case depending on the Company’s total leverage ratio. In no event will Term SOFR, Eurocurrency Rate or CDOR Rate be less than 0.00 % per annum. As of March 31, 2023 , borrowings under the Credit Facility were $ 20.0 million ( December 31, 2022 — $ 25.0 million) and bear interest at Term SOFR, plus a margin of 1.75 % per annum based on the Company’s total leverage ratio. The effective interest rate for the three months ended March 31, 2023 was 6.35 %. There were no amounts drawn under the Credit Facility during the three months ended March 31, 2022. The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit indebtedness, liens, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets. The Credit Agreement also contains customary representations, warranties and event of default provisions. The Company incurred fees of approximately $ 2.5 million in connection with the March 25, 2022 amendment of the Credit Agreement, which are being amortized on a straight-line basis over the term of the Credit Agreement. In the first quarter of 2022, the Company expensed $ 0.4 million in unamortized deferred financing costs associated with lenders that are no longer parties to the Credit Agreement. As of March 31, 2023 and December 31, 2022 , the Company did no t have any letters of credit or advance payment guarantees outstanding under the Credit Facility. As of March 31, 2023 , the amount available for future borrowings under the Credit Facility was $ 280.0 million. Foreign Exchange Facility Within the Credit Facility, the Company is able to purchase foreign currency forward contracts and/or other swap arrangements. As of March 31, 2023, the net unrealized loss on the Company’s outstanding foreign currency forward contracts was $( 0.2 ) million , representing the amount by which the notional value of these forward contracts exceeded their fair value (December 31, 2022 — net unrealized loss of $( 0.6 ) million). As of March 31, 2023, the notional value of the Company’s outstanding foreign currency forward contracts was $ 34.4 million (December 31, 2022 — $ 24.7 million ). Bank of China Facility In June 2022, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company’s majority-owned subsidiaries in China, renewed its unsecured revolving facility with Bank of China for up to 200.0 million Chinese Renminbi (“RMB”) ($ 29.1 million), including RMB 10.0 million ($ 1.4 million) for letters of guarantee, to fund ongoing working capital requirements (the “Bank of China Facility”). The Bank of China Facility expires in September 2023 . As of March 31, 2023, RMB 2.6 million ($ 0.4 million) of borrowings were outstanding under the Bank of China Facility and outstanding letters of guarantee were RMB 3.0 million ( $ 0.4 million ). As of December 31, 2022, outstanding Bank of China Facility borrowings were RMB 2.6 million ( $ 0.4 million ) and outstanding letters of guarantee were RMB 2.8 million ( $ 0.4 million ). As of March 31, 2023, the amount available for future borrowings under the Bank of China Facility was RMB 187.4 million ( $ 27.3 million ) and the amount available for letters of guarantee was RMB 7.0 million ( $ 1.0 million ). The amount available for future borrowings under the Bank of China Facility is not subject to a standby fee. The effective interest rate for the three months ended March 31, 2023 was 3.85 % (2022 — 4.15 % ). HSBC China Facility In June 2022, IMAX Shanghai entered into an unsecured revolving facility for up to RMB 200.0 million ($ 29.1 million) with HSBC Bank (China) Company Limited, Shanghai Branch to fund ongoing working capital requirements (the “HSBC China Facility”). As of March 31, 2023 , RMB 83.6 million ($ 12.2 million) of borrowings were outstanding under the HSBC China Facility. As of December 31, 2022, outstanding HSBC China Facility borrowings were RMB 87.0 million ($ 12.5 million). As of March 31, 2023, the amount available for future borrowings under the HSBC China Facility was RMB 116.4 million ($ 16.9 million). The effective interest rate for the three months ended March 31, 2023 was 3.88 % (2022 — 3.91 %). NBC Facility In October 2019, the Company entered into a $ 5.0 million facility with National Bank of Canada (the “NBC Facility”) fully insured by Export Development Canada for use solely in conjunction with the issuance of performance guarantees and letters of credit. The NBC Facility will expire on June 30, 2023 , and is renewable on the same terms and conditions on an annual basis. The Company did no t have any letters of credit or advance payment guarantees outstanding as of March 31, 2023 and December 31, 2022 under the NBC Facility. (b) Convertible Notes and Other Borrowings, Net As of March 31, 2023 and December 31, 2022, Convertible Notes and Other Borrowings, Net includes the following: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Convertible Notes $ 230,000 $ 230,000 Unamortized discounts and debt issuance costs ( 4,494 ) ( 4,870 ) Convertible Notes, net 225,506 225,130 Federal Economic Development Loan 3,128 2,812 Unaccreted interest benefit ( 1,085 ) ( 1,030 ) Federal Economic Development Loan, net 2,043 1,782 Convertible Notes and Other Borrowings, net $ 227,549 $ 226,912 Convertible Notes On March 19, 2021, the Company issued $ 230.0 million of 0.500 % Convertible Senior Notes due 2026 (the “Convertible Notes”) in a private placement conducted pursuant to Rule 144A under the Securities Act of 1933, as amended. The net proceeds from the issuance of the Convertible Notes were $ 223.7 million, after deducting the initial purchasers ’ discounts and commissions. The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500 % per annum on the principal of $ 230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021 . The Convertible Notes will mature on April 1, 2026 , unless they are redeemed or repurchased by the Company or converted on an earlier date. Holders of the Convertible Notes have the right to convert their Convertible Notes in certain circumstances and during specified periods. Before January 1, 2026, holders of the Convertible Notes have the right to convert their Convertible Notes only upon the occurrence of certain events. From and after January 1, 2026, holders of the Convertible Notes may convert their Convertible Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as applicable, cash or a combination of cash (in an amount no less than the principal amount of the Convertible Notes being converted) and common shares, at its election, based on the applicable conversion rates. The initial conversion rate is 34.7766 common shares per $ 1,000 principal amount of Convertible Notes, which represents an initial conversion price of approximately $ 28.75 per common share, and is subject to adjustment upon the occurrence of certain events. The Convertible Notes are redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after April 6, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock exceeds 130 % of the conversion price for a specified period of time. In addition, calling any Convertible Notes for redemption will constitute a “make-whole fundamental change” with respect to such notes, in which case the conversion rate applicable to the conversion of such notes will be increased in certain circumstances if such notes are converted after they are called for redemption. In addition, upon the occurrence of a “fundamental change” (as defined below), holders may require the Company to repurchase their Convertible Notes at a cash repurchase price equal to the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any. Subject to the terms and conditions of the indenture governing the Convertible Notes, a “fundamental change” means, among other things, an event resulting in (i) a change of control, (ii) a transfer of all or substantially all of the assets of the Company, (iii) a merger, (iv) liquidation or dissolution of the Company, or (v) delisting of the Company’s common shares from a national securities exchange. The Company recorded the Convertible Notes entirely as a liability in the Condensed Consolidated Balance Sheets, net of initial purchasers’ discounts and commissions and other debt issuance costs, with interest expense reflecting the cash coupon plus the amortization of the discounts and capitalized costs. Additionally, under the “if-converted” method, because the principal amount of the Convertible Notes is settled in cash and the conversion spread is settleable in the Company’s common shares, diluted earnings per share is calculated by including the net number of incremental shares that would be issued upon conversion of the Convertible Notes, using the average market price during the period. Accordingly, the application of the “if-converted” method may reduce the Company’s reported diluted earnings per share. In connection with the pricing of the Convertible Notes, the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”) with certain financial institutions. The Capped Call Transactions are expected to reduce potential dilution resulting from the common shares the Company is required to issue and/or to offset any potential cash payments the Company is required to make in excess of the principal amount of the Convertible Notes in the event that the market price per share of the Company’s common shares is greater than the strike price of the Capped Call Transactions with such reduction and/or offset subject to a cap. The Capped Call Transactions have an initial cap price of $ 37.2750 per share of the Company’s common shares, which represents a premium of 75 % over the last reported sale price of the common shares when they were priced on March 16, 2021, and are subject to certain adjustments under the terms of the Capped Call Transactions. Collectively, the Capped Call Transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of the Company’s common shares underlying the Convertible Notes. The cost of the Capped Call Transactions was approximately $ 19.1 million. The Capped Call Transactions are separate transactions, are not part of the terms of the Convertible Notes and will not affect any holder’s rights under the Convertible Notes. Holders of the Convertible Notes will not have any rights with respect to the Capped Call Transactions. The Capped Call Transactions meet all of the applicable criteria for equity classification in accordance with ASC 815-10-15-74(a), “Derivatives and Hedging—Embedded Derivatives—Certain Contracts Involving an Entity’s Own Equity,” and, as a result, the related $ 19.1 million cost was recorded as a reduction to Other Equity within Shareholders’ Equity on the Company’s Condensed Consolidated Statements of Shareholders' Equity and Condensed Consolidated Balance Sheets. Federal Economic Development Loan The Company's wholly-owned subsidiary, SSIMWAVE, entered into a contribution agreement with the Federal Economic Development Agency for Southern Ontario (the “Federal Economic Development Loan” ) on May 29, 2019, under which SSIMWAVE received $ 4.2 million Canadian Dollars ( “CAD” ) ($ 3.1 million) by way of repayable contributions toward certain eligible projects costs. The contributions under the agreement cover 35 % of the eligible and supported costs of SSIMWAVE between January 10, 2019 and December 31, 2022. The contributions are repayable over 60 months , with repayments estimated to begin in January 2024 , with an annual interest rate of 0 %. The benefit of the interest free loan has been determined by calculating the present value of the payments using a market-based interest rate and comparing this to the proceeds received. The benefit is being recorded as the interest free benefit of government funding within Interest Income on the Condensed Consolidated Statements of Operations. The benefit, which was $ 0.1 million for the three months ended March 31, 2023 , was recorded as the interest free benefit of government funding within Interest Income on the Condensed Consolidated Statements of Operations. The obligation is being accreted to its maturity amount, resulting in an interest expense of less than $ 0.1 million during the three months ended March 31, 2023 and is being recorded within Interest Expense on the Company’s Condensed Consolidated Statements of Operations. As of March 31, 2023, the Federal Economic Development Loan has a carrying value of $ 2.0 million , net of unaccreted interest benefit and is recorded within Convertible Notes and Other Borrowings, Net on the Company’s Condensed Consolidated Balance Sheets.

Commitments, Contingencies and

Commitments, Contingencies and Guarantees	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Guarantees	7. Commitments, Contingencies and Guarantees (a) Commitments In the ordinary course of its business, the Company enters into contractual agreements with third parties that include non-cancellable payment obligations, for which it is liable in future periods. These arrangements can include terms binding the Company to minimum payments and/or penalties if it terminates the agreement for any reason other than an event of default as described by the agreement. (b) Contingencies and guarantees The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company records a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management’s judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred. (i) In January 2004, the Company and IMAX Theatre Services Ltd., a subsidiary of the Company, commenced an arbitration seeking damages before the International Court of Arbitration of the International Chamber of Commerce (the “ICC”) with respect to the breach by Electronic Media Limited (“EML”) of its December 2000 agreement with the Company. In June 2004, the Company commenced a related arbitration before the ICC against EML’s affiliate, E-City Entertainment (I) PVT Limited (“E-City”). On March 27, 2008, the arbitration panel issued a final award in favor of the Company in the amount of $ 11.3 millio n, as well as an additional $ 2,512 each day in interest from October 1, 2007 until the date the award is paid . In July 2008, E-City commenced a proceeding in Mumbai, India seeking to prevent recognition of the ICC award in India. On March 10, 2017, the Supreme Court of India dismissed E-City’s petition. On March 29, 2017, the Company filed an Execution Application in the Bombay High Court seeking to enforce the ICC award against E-City and several related parties, which award the Company calculates to be $ 25.5 million , inclusive of interest, as of March 31, 2023 . That matter is currently pending. The Company has also taken steps to enforce the ICC final award outside of India. In December 2011, the Ontario Superior Court of Justice issued an order recognizing the final award and requiring E-City to pay the Company $ 30,000 to cover the costs of the application , and in May 2012, the New York Supreme Court recognized the Canadian judgment and entered it as a New York judgment. The Company intends to continue pursuing its rights and seeking to enforce the award, although no assurances can be given with respect to the ultimate outcome. (ii) In addition to the matters described above, the Company is currently involved in other legal proceedings or governmental inquiries which, in the opinion of the Company’s management, will not materially affect the Company’s financial position or future operating results, although no assurance can be given with respect to the ultimate outcome of any such proceedings. (iii) In the normal course of business, the Company enters into agreements that may contain features that meet the definition of a guarantee. A guarantee is a contract (including an indemnity) that contingently requires the Company to make payments (either in cash, financial instruments, other assets, shares of its stock, or provision of services) to a third party based on (a) changes in an underlying interest rate, foreign exchange rate, equity or commodity instrument, index or other variable, that is related to an asset, a liability or an equity security of the counterparty, (b) failure of another party to perform under an obligating agreement or (c) failure of another third party to pay its indebtedness when due. (c) Financial Guarantees Certain subsidiaries of the Company have provided significant financial guarantees to third parties under the Credit Agreement. (d) Product Warranties The Company’s accrual for product warranties, which is recorded within Accrued and Other Liabilities in the Condensed Consolidated Balance Sheets, was $ 0.1 million and $ nil as of March 31, 2023 and December 31, 2022, respectively. (e) Director and Officer Indemnifications The Company’s by-laws contain an indemnification of its current directors and officers, former directors and officers, and persons who have acted at its request to be a director and/or officer of an entity in which the Company is a shareholder or creditor, to indemnify them, to the extent permitted by the Canada Business Corporations Act , against expenses (including legal fees), judgments, fines and any amounts actually and reasonably incurred by them in connection with any action, suit or proceeding in which the directors and/or officers are sued as a result of their service, if they acted honestly and in good faith with a view to the best interests of the Company. In addition, the Company has entered into indemnification agreements with each of its directors in order to effectuate the foregoing. The nature of the indemnification prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. The Company has purchased directors’ and officers’ liability insurance. No amount has been accrued in the Company’s Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022, with respect to this indemnity. (f) Other Indemnification Agreements In the normal course of its operations, the Company provides indemnifications to counterparties in transactions such as: IMAX System lease and sale agreements and the supervision of installation or servicing of IMAX Systems; film production, exhibition and distribution agreements; real property lease agreements; and employment agreements. These indemnification agreements require the Company to compensate the counterparties for costs incurred as a result of litigation claims that may be suffered by the counterparty as a consequence of the transaction or the Company’s breach or non-performance under these agreements. While the terms of these indemnification agreements vary based upon the contract, they normally extend for the life of the agreements. A small number of agreements do not provide for any limit on the maximum potential amount of indemnification; however, virtually all of the IMAX System lease and sale agreements limit such maximum potential liability to the purchase price of the system. The fact that the maximum potential amount of indemnification required by the Company is not specified in some cases prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. Historically, the Company has no t made any significant payments under such indemnifications and no amounts have been accrued in the Condensed Consolidated Financial Statements with respect to the contingent aspect of these indemnities.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Operations Supplemental Information	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidated Statements of Operations Supplemental Information	8. Condensed Consolidated Statements of Operations – Supplemental Information (a) Selling Expenses The following table summarizes the Company’s selling expenses, including sales commissions and marketing and other, which are recognized within Costs and Expenses Applicable to Revenues in the Condensed Consolidated Statements of Operations, for three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 2022 (In thousands of U.S. Dollars) Sales Marketing Sales Marketing Technology sales (1) $ 200 $ 16 $ — $ 162 Image enhancement and maintenance services (2) — 6,772 — 2,915 Technology rentals (3) 73 260 45 465 Total $ 273 $ 7,048 $ 45 $ 3,542 (1) Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred. (2) Film exploitation costs, including advertising and marketing costs, are expensed as incurred. (3) Sales commissions related to joint revenue sharing arrangements accounted for operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed. Direct advertising and marketing costs for each IMAX System are expensed as incurred. (b) Foreign Exchange Included in Selling, General and Administrative Expenses for the three months ended March 31, 2023 is a foreign currency net loss of $( 0.1 ) million , (2022 — foreign currency net loss of $( 0.1 ) million ) resulting from changes in exchange rates related to foreign currency denominated monetary assets and liabilities. (See Note 15(c) for additional information.) (c) Collaborative Arrangements Joint Revenue Sharing Arrangements The accounting policy for the Company’s joint revenue sharing arrangements is disclosed in Note 3(o) of the Company’s audited Consolidated Financial Statements in its 2022 Form 10-K. Revenue attributable to transactions arising between the Company and its customers under joint revenue sharing arrangements are recorded within Revenues — Technology Sales (for hybrid joint revenue sharing arrangements) and Revenues — Technology Rentals (for traditional joint revenue sharing arrangements). For the three months ended March 31, 2023, such revenues totaled $ 20.1 million (2022 — $ 13.6 million ). IMAX Film Remastering and Distribution In an IMAX film remastering and distribution (formerly known as “IMAX DMR”) arrangement, the Company receives a percentage of the box office receipts from a third party who owns the copyright to a film in exchange for converting the film into IMAX format and distributing it through the IMAX network . The fee earned by the Company in a typical IMAX film remastering and distribution arrangement averages approximately 12.5 % of box office receipts (i.e. gross box office receipts less applicable sales taxes), except for within Greater China, where the Company receives a lower percentage of net box office receipts for certain Hollywood films. The accounting policy for the Company’s IMAX film remastering and distribution arrangements is disclosed in Note 3(o) of the Company’s audited Consolidated Financial Statements in its 2022 Form 10-K. Revenue attributable to transactions arising between the Company and its customers under IMAX film remastering and distribution arrangements are included in Revenues – Image Enhancement and Maintenance Services. For the three months ended March 31, 2023, such revenues totaled $ 30.1 million (2022 — $ 19.6 million ). (See Note 12(a) for a disaggregated presentation of the Company’s revenues.) Co-Produced Film Arrangements In certain film arrangements, the Company co-produces a film with a third party whereby the third party retains the copyright and certain other rights to the film. In some cases, the Company obtains exclusive theatrical distribution rights to the film. Under these arrangements, both parties contribute to the funding of the production, distribution and exploitation costs associated with the film. As of March 31, 2023 , the Company is party to one co-produced film arrangement, which represents the VIE total assets balance of $ 1.5 million and liabilities balance of $ 0.2 million , and four other co-produced film arrangements, the terms of which are similar. The accounting policies relating to co-produced film arrangements are disclosed in Notes 3(a) and 3(o) of the Company’s 2022 Form 10-K. For the three months ended March 31, 2023, an expense of $ 0.1 million (2022 — $ 0.1 million ) attributable to transactions between the Company and other parties involved in the production of the films have been included in Costs and Expenses Applicable to Revenues ― Image Enhancement and Maintenance Services.

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows Supplemental Information	3 Months Ended
	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Condensed Consolidated Statements of Cash Flows Supplemental Information	9. Condensed Consolidated Statements of Cash Flows – Supplemental Information (a) Changes in other operating assets and liabilities Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 (Increase) decrease in: Financing receivables $ ( 1,625 ) $ 3,916 Prepaid expenses ( 2,406 ) ( 2,413 ) Variable consideration receivables ( 3,440 ) 829 Other assets 80 209 Increase (decrease) in: Accounts payable 513 2,184 Accrued and other liabilities ( 1,466 ) ( 14,911 ) $ ( 8,344 ) $ ( 10,186 ) (b) Depreciation and amortization Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Film assets $ 3,452 $ 3,178 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements 5,772 5,548 Other property, plant and equipment (1) 2,287 2,028 Other intangible assets (2) 1,399 1,532 Other assets (3) 410 455 $ 13,320 $ 12,741 (1) Includes the amortization of laser projection systems, camera, and lens upgrades recorded in Research and Development on the Condensed Consolidated Statement of Operations of $ 0.1 million in the three months ended March 31, 2023 (2022 — $ 0.2 million ). (2) Includes the amortization of licenses and intellectual property recorded in Research and Development on the Condensed Consolidated Statement of Operations of $ 0.3 million in the three months ended March 31, 2023 (2022 — $ 0.3 million ). (3) Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements. (c) Write-downs Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements (1) $ 297 $ 202 Other property, plant and equipment 1 2 Inventories 6 12 Film assets — 165 $ 304 $ 381 (1) In the three months ended March 31, 2023, the Company recorded charges of $ 0.3 million (2022 — $ 0.2 million ) in Costs and Expenses Applicable to Revenues ― Technology Rentals mostly related to the write-down of leased xenon-based digital systems which were taken out of service in connection with customer upgrades to laser-based digital systems, as well as the closure of one IMAX System. (d) Significant non-cash investing activities Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Net (decrease) increase in accruals related to: Investment in equipment supporting joint revenue sharing arrangements $ ( 764 ) $ 1,133 Acquisition of other intangible assets ( 22 ) 32 Purchases of property, plant and equipment 548 — $ ( 238 ) $ 1,165

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes (a) Income Tax Expense For the three months ended March 31, 2023, the Company recorded income tax expense of $ 4.9 million (2022 — $ 2.6 million ). For the three months ended March 31, 2023, the Company’s effective tax rate differs from the combined Canadian federal and provincial statutory income tax rate due to the following factors: Three Months Ended Three Months Ended March 31, 2023 March 31, 2022 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Income tax (expense) benefit at combined statutory rates $ ( 2,652 ) 26.5 % $ 2,475 26.5 % Adjustments resulting from: Increase in valuation allowance ( 1,610 ) 16.1 % ( 5,009 ) ( 53.6 %) Shortfall tax benefits related to share-based compensation ( 83 ) 0.8 % ( 129 ) ( 1.4 %) Changes to tax reserves ( 258 ) 2.6 % ( 160 ) ( 1.7 %) Other ( 282 ) 2.8 % 213 2.3 % Income tax expense $ ( 4,885 ) 48.8 % $ ( 2,610 ) ( 27.9 %) As of March 31, 2023, the Company’s Condensed Consolidated Balance Sheets include deferred income tax assets of $ 11.2 million , net of a valuation allowance of $ 64.5 million (December 31, 2022 — $ 9.9 million , net of a valuation allowance of $ 62.9 million ). For the three months ended March 31, 2023, the Company recorded an additional $ 1.6 million (2022 — $ 5.0 million ) valuation allowance where management cannot determine that the tax benefits will be realizable based on available evidence. The increase in the valuation allowance recorded in the three months ended March 31, 2023 and 2022 is reflected within Income Tax Expense in the Company's Condensed Consolidated Statements of Operations. The valuation allowance is expected to reverse at the point in time when management determines it is more likely than not that the Company will incur sufficient tax liabilities to allow it to utilize the deferred tax assets against which the valuation allowance is recorded. As of March 31, 2023, the Company's Condensed Consolidated Balance Sheets also include deferred tax liabilities of $ 16.0 million (December 31, 2022 — $ 14.9 million ). (b) Income Tax Effect on Other Comprehensive Income For the three months ended March 31, 2023 and 2022, the Income Tax Expense related to the components of Other Comprehensive Income (“OCI”) is as follows: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Unrealized change in cash flow hedging instruments $ ( 35 ) $ ( 82 ) Realized change in cash flow hedging instruments ( 89 ) ( 8 ) Defined benefit and postretirement benefit plans 46 ( 12 ) $ ( 78 ) $ ( 102 )

Capital Stock and Reserves

Capital Stock and Reserves	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Capital Stock and Reserves	11. Capital Stock and Reserves (a) Share-Based Compensation For the three months ended March 31, 2023, share-based compensation expense totaled $ 5.1 million (2022 — $ 6.1 million ) and is reflected in the following accounts in the Condensed Consolidated Statements of Operations: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Costs and expenses applicable to revenues $ 263 $ 239 Selling, general and administrative expenses 5,196 5,726 Research and development 99 87 Executive transition costs ( 499 ) — $ 5,059 $ 6,052 The following table summarizes the Company’s share-based compensation expense by each award type: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Stock Options $ 84 $ 207 Restricted Share Units 3,365 3,411 Performance Stock Units 924 1,729 IMAX China Stock Options 10 34 IMAX China Long Term Incentive Plan Restricted Share Units 541 497 IMAX China Long Term Incentive Plan Performance Stock Units 135 174 $ 5,059 $ 6,052 For the three months ended March 31, 2023 and 2022 , the Company did no t record any expenses related to restricted share units granted to non-employees. Stock Option Summary The following table summarizes the activity under the Company’s Stock Option Plan (“SOP”) and the IMAX Corporation Second Amended and Restated Long-Term Incentive Plan (as may be amended, “IMAX LTIP”) for the three months ended March 31, 2023 and 2022: Number of Shares Weighted Average Exercise 2023 2022 2023 2022 Stock options outstanding, beginning of period 3,604,739 3,736,157 $ 26.36 $ 26.61 Granted — — — — Exercised — — — — Forfeited — — — — Expired ( 144,366 ) ( 126,569 ) 31.85 33.61 Cancelled — ( 2,197 ) — 32.50 Stock options outstanding, end of period 3,460,373 3,607,391 26.13 26.36 Stock options exercisable, end of period 3,460,373 3,524,298 26.13 26.45 Stock options are no longer granted under the Company’s previously approved SOP. IMAX LTIP Restricted Share Units (“RSU”) Summary The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the three months ended March 31, 2023 and 2022: Number of Awards Weighted Average Grant Date 2023 2022 2023 2022 RSUs outstanding, beginning of period 1,252,044 1,457,883 $ 19.16 $ 19.16 Granted 811,529 636,427 17.73 19.64 Vested and settled ( 677,611 ) ( 648,527 ) 18.70 18.78 Forfeited ( 19,509 ) ( 1,328 ) 19.80 14.84 RSUs outstanding, end of period 1,366,453 1,444,455 18.53 19.54 IMAX LTIP Performance Stock Units (“PSU”) Summary The Company grants two types of PSU awards, one which vests based on a combination of employee service and the achievement of certain EBITDA-based targets and one which vests based on a combination of employee service and the achievement of total shareholder return (“TSR”) targets. The achievement of the EBITDA and TSR targets in these PSUs is determined over a three-year performance period. At the conclusion of the three-year performance period, the number of PSUs that ultimately vest can range from 0 % to a maximum vesting opportunity of 175 % of the initial award, depending upon actual performance versus the established EBITDA and stock-price targets. The grant date fair value of PSUs with EBITDA-based targets is equal to the closing price of the Company’s common shares on the date of grant or the average closing price of the Company’s common shares for five days prior to the date of grant. The grant date fair value of PSUs with TSR targets is determined on the grant date using a Monte Carlo simulation, which is a valuation model that considers the likelihood of achieving the TSR targets embedded in the award (“Monte Carlo Model”). The compensation expense attributable to each type of PSU is recognized on a straight-line basis over the requisite service period. The fair value determined by the Monte Carlo Model is affected by the Company’s share price, as well as assumptions regarding a number of complex and subjective variables. These variables include, but are not limited to, market conditions as of the grant date, the Company’s expected share price volatility over the term of the awards, and other relevant data. The compensation expense is fixed on the date of grant based on the fair value of the PSUs granted. The amount and timing of compensation expense recognized for PSUs with EBITDA-based targets is dependent upon management’s assessment of the likelihood of achieving these targets. If, as a result of management’s assessment, it is projected that a greater number of PSUs will vest than previously anticipated, a life-to-date adjustment to increase compensation expense is recorded in the period that such determination is made. Conversely, if, as a result of management’s assessment, it is projected that a lower number of PSUs will vest than previously anticipated, a life-to-date adjustment to decrease compensation expense is recorded in the period that such determination is made. The expense recognized in the three months ended March 31, 2023 and 2022 includes adjustments reflecting management’s estimate of the number of PSUs with EBITDA-based targets expected to vest. The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP for the three months ended March 31, 2023 and 2022: Number of Awards Weighted Average Grant Date 2023 2022 2023 2022 PSUs outstanding, beginning of period 931,716 613,405 $ 18.96 $ 18.21 Granted (1) 580,118 359,138 17.68 20.34 Forfeited ( 208,648 ) — 18.09 — Vested and settled (1) ( 368,602 ) — 16.92 — PSUs outstanding, end of period 934,584 972,543 19.16 19.00 (1) For the three months ended March 31, 2023 , the balance of shares granted includes 157,963 additional shares, at a weighted average grant date fair value per share of $ 16.92 , as PSUs granted in 2020 with EBITDA-based targets vested at 175 % on account of full achievement of the targets. This performance adjustment in the first quarter of 2023 reflects the Company's performance assessment of its first PSU awards. As of March 31, 2023 , the maximum number of shares of common stock that may be issued with respect to PSUs outstanding is 1,635,522 , assuming full achievement of the EBITDA and TSR targets. (b) Issuer Purchases of Equity Securities In 2022, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2023 and an increase of $ 200.0 million in the share repurchase program. With the increase of $ 200.0 million, the Company ’ s total share repurchase authority is $ 400.0 million under the current share repurchase program. As of March 31, 2023 , the Company has $ 191.8 million available under its approved repurchased program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. During the three months ended March 31, 2023, the Company repurchased 109,477 common shares, at an average price of $ 14.87 per share, for a total of $ 1.6 million , excluding commissions. The repurchases for the three months ended March 31, 2023 excludes repurchases of 140,000 shares with trade dates in December 2022, which were settled in January 2023 at an average price of $ 14.45 per share, for a total of $ 2.0 million, excluding commissions. During the three months ended March 31, 2022, the Company repurchased 380,652 common shares, at an average price of $ 16.45 per share, for a total of $ 6.3 million , excluding commissions. During the three months ended March 31, 2023 and 2022 , there were no shares purchases in the administration of employee share based plans. As of March 31, 2023 and December 31, 2022 , the IMAX LTIP trustee did no t hold any shares. Any shares held with the trustee are recorded at cost and are reported as a reduction against Capital Stock on the Company’s Condensed Consolidated Balance Sheets. In 2022, IMAX China Holding, Inc. (“IMAX China”)’s shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10 % of the total number of issued shares as of June 23, 2022 ( 34,063,480 shares). This program will be valid until the 2023 Annual General Meeting of IMAX China on June 6, 2023. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time. During the three months ended March 31, 2023 , IMAX China did no t repurchase any common shares. During the three months ended March 31, 2022, IMAX China repurchased 1,448,000 common shares, at an average price of HKD 9.89 per share, ( $ 1.26 per share) for a total of HKD 14.3 million ( $ 1.8 million ). During the three months ended March 31, 2023 and 2022 , there were no shares purchases in the administration of employee share based plans. The change in the non-controlling interest attributable to IMAX China as a result of common shares repurchased is recorded as a reduction to Non-Controlling Interests in the Condensed Consolidated Balance Sheets and the Condensed Consolidated Statements of Shareholders’ Equity. The difference between the consideration paid and the ownership interest obtained as a result of IMAX China share repurchases is recorded within Other Equity in the Condensed Consolidated Balance Sheets and the Condensed Consolidated Statements of Shareholders’ Equity. (c) Basic and Diluted Weighted Average Shares Outstanding The following table reconciles the denominator of the basic and diluted weighted average share computations: Three Months Ended March 31, 2023 2022 (In thousands) Issued and outstanding, beginning of period 54,149 58,654 Weighted average number of shares repurchased, net ( 85 ) ( 80 ) Weighted average number of shares outstanding - basic 54,064 58,574 Weighted average effect of potential common shares, if dilutive 927 — Weighted average number of shares outstanding - diluted 54,991 58,574 For the three months ended March 31, 2023, the calculation of diluted weighted average shares outstanding excludes 4,260,382 shares (2022 — 6,348,736 shares) that are issuable upon the vesting or exercise of share-based compensation including: (i) 620,553 RSUs (2022 — 1,444,455 RSUs), (ii) 179,456 PSUs (2022 — 1,296,890 PSUs) and (iii) 3,460,373 stock options (2022 — 3,607,391 stock options), as the effect would be anti-dilutive. The calculation of diluted weighted average shares outstanding for the three months ended March 31, 2023 and 2022 also excludes any shares potentially issuable upon the conversion of the Convertible Notes as the average market price of the Company’s common shares during the period of time they were outstanding was less than the conversion price of the Convertible Notes. (d) Statutory Surplus Reserve Pursuant to the corporate law of the PRC, entities registered in the PRC are required to maintain certain statutory reserves, which are appropriated from after-tax profits (after offsetting accumulated losses from prior years), as reported in their respective statutory financial statements, before the declaration or payment of dividends to equity holders. All statutory reserves are created for specific purposes. The Company’s PRC subsidiaries are required to appropriate 10 % of statutory net profits to statutory surplus reserves, upon distribution of their after-tax profits. The Company’s PRC subsidiaries may discontinue the contribution when the aggregate sum of the statutory surplus reserve is more than 50 % of its registered capital. The statutory surplus reserve is non-distributable other than during liquidation and may only be used to fund losses from prior years, to expand production operations, or to increase the capital of the subsidiaries. In addition, the subsidiaries may make further contribution to the discretional surplus reserve using post-tax profits in accordance with resolutions of the Board of Directors. The statutory surplus reserve of RMB 36.4 million ($ 5.6 million) has reached 50 % of its PRC subsidiaries’ registered capital.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	12. Revenue from Contracts with Customers (a) Disaggregated Information About Revenue In the first quarter of 2023, the Company updated its reportable segments (see Note 13 ). Prior period comparatives have been revised to conform with the current period presentation. The following tables summarize the Company’s Revenues by reportable segment and revenue stream type for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 (In thousands of U.S. Dollars) Technology Sales Image Enhancement Technology Rentals Finance Income Total Content Solutions Segment Film Remastering and Distribution $ — $ 30,073 $ — $ — $ 30,073 Other Content Solutions — 2,028 — — 2,028 — 32,101 — — 32,101 Technology Products and Services Segment System Sales 16,119 — — — 16,119 System Rentals — — 20,058 — 20,058 Maintenance — 13,551 — — 13,551 Finance Income — — — 1,939 1,939 16,119 13,551 20,058 1,939 51,667 Sub-total for reportable segments 16,119 45,652 20,058 1,939 83,768 All Other 1,703 1,475 — — 3,178 Total $ 17,822 $ 47,127 $ 20,058 $ 1,939 $ 86,946 Three Months Ended March 31, 2022 (In thousands of U.S. Dollars) Technology Sales Image Enhancement and Maintenance Services Technology Rentals Finance Income Total Content Solutions Segment Film Remastering and Distribution $ — $ 19,564 $ — $ — $ 19,564 Other Content Solutions — 1,406 18 — 1,424 — 20,970 18 — 20,988 Technology Products and Services Segment System Sales 7,973 — — — 7,973 System Rentals — — 12,643 — 12,643 Maintenance — 14,942 — — 14,942 Finance Income — — — 2,305 2,305 7,973 14,942 12,643 2,305 37,863 Sub-total for reportable segments 7,973 35,912 12,661 2,305 58,851 All Other 1,003 182 — — 1,185 Total $ 8,976 $ 36,094 $ 12,661 $ 2,305 $ 60,036 For the three months ended March 31, 2023, revenues earned from Technology Sales includes variable consideration of $ 5.6 million (2022 — $ 0.4 million). Variable consideration revenues represent an estimate of the contingent fees that may become due if certain annual minimum box office receipt thresholds are exceeded and are recorded as revenue in the period when the sale is recognized and may be adjusted in future periods based on actual results and changes in estimates over the term of the system agreement. For the three months ended March 31, 2023, revenues earned from leasing arrangements total $ 22.4 million (2022 — $ 13.6 million), including $ 20.1 million in Revenues ― Technology Rentals (2022 — $ 12.6 million), and $ 2.3 million in Revenues ― Technology Sales (2022 — $ 1.0 million). (b) Deferred Revenue IMAX System sale and lease arrangements include a requirement for the Company to provide maintenance services over the life of the arrangement, some of which are subject to a consumer price index adjustment each year. In circumstances where customers prepay the entire term’s maintenance fee based on the original arrangement, additional payments are due to the Company for the years after its extended warranty and maintenance obligations expire. Payments, upon renewal each year, are either prepaid or made in arrears and can vary in frequency from monthly to annually. As of March 31, 2023, $ 22.2 million of consideration has been deferred in relation to outstanding maintenance services to be provided on existing maintenance contracts (December 31, 2022 — $ 21.0 million ). Maintenance revenue is recognized evenly over the contract term which coincides with the period over which maintenance services are provided. In the event of customer default, any payments made by the customer may be retained by the Company. In instances where the Company receives consideration prior to satisfying its performance obligations, the recognition of revenue is deferred. The majority of the deferred revenue balance relates to payments received by the Company for IMAX Systems where control of the system has not yet transferred to the customer. The deferred revenue balance related to an individual IMAX System increases as progress payments are made and is then derecognized when control of the system is transferred to the customer. Recognition dates are variable and depend on numerous factors, including some outside of the Company’s control.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Reporting	13. Segment Reporting The Company ’ s Chief Executive Officer (“CEO”) is its Chief Operating Decision Maker (“CODM”), as such term is defined under U.S. GAAP. The CODM assesses segment performance based on segment revenues and segment gross margins. Selling, general and administrative expenses, research and development costs, the amortization of intangible assets, provision for (reversal of) current expected credit losses, certain write-downs, interest income, interest expense, and income tax (expense) benefit are not allocated to the Company ’ s segments. In the first quarter of 2023, the Company revised its internal segment reporting, including the information provided to the CODM to assess segment performance and allocate resources. Accordingly, the Company has two reportable segments: (i) Content Solutions, which principally includes content enhancement and distribution services, previously included within the IMAX DMR, Film Distribution and Film Post-Production segments, and (ii) Technology Products and Services, which principally includes the sale, lease, and maintenance of IMAX Systems, previously included within the JRSA, IMAX Systems, IMAX Maintenance, and Other Theater Business segments. The Company’s activities that do not meet the criteria to be considered a reportable segment are reported within All Other. Prior period comparatives have been revised to conform with the current period presentation. The Company has the following reportable segments: (i) Content Solutions, which principally includes the digital remastering of films and other content into IMAX formats for distribution to the IMAX network. To a lesser extent, the Content Solutions segment also earns revenue from the distribution of large-format documentary films and exclusive experiences ranging from live performances to interactive events with leading artists and creators, as well as film post-production services. (ii) Technology Products and Services, which includes results from the sale or lease of IMAX Systems, as well as from the maintenance of IMAX Systems. To a lesser extent, the Technology Product and Services segment also earns revenue from certain ancillary theater business activities, including after-market sales of IMAX System parts and 3D glasses. Transactions between segments are valued at exchange value. Inter-segment profits are eliminated upon consolidation, as well as for the disclosures below. The following table presents the Company’s revenue and gross margin by reportable segment for the three months ended March 31, 2023 and 2022: Revenue (1) Gross Margin (In thousands of U.S. Dollars) 2023 2022 2023 2022 Content Solutions $ 32,101 $ 20,988 $ 17,995 $ 12,625 Technology Products and Services 51,667 37,863 29,891 18,416 Sub-total for reportable segments 83,768 58,851 47,886 31,041 All Other (2) 3,178 1,185 2,165 730 Total $ 86,946 $ 60,036 $ 50,051 $ 31,771 (1) The Company’s largest customer represents 9 % of total Revenues for the three months ended March 31, 2023 (2022 — 11 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of March 31, 2023 and December 31, 2022 . (2) All Other includes the results from IMAX Enhanced , SSIMWAVE, and other ancillary activities. Geographic Information Revenue by geographic area is based on the location of the customer. Revenue related to IMAX film remastering and distribution is presented based upon the geographic location of the IMAX System that exhibits the remastered films. IMAX film remastering and distribution revenue is generated through contractual relationships with studios and other third parties and these may not be in the same geographical location as the IMAX System. The following table summarizes the Company’s revenues by geographic area for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 United States $ 26,753 $ 19,067 Greater China 26,566 21,476 Asia (excluding China) 10,652 5,767 Western Europe 10,168 7,061 Canada 7,196 1,772 Latin America 1,603 1,886 Russia/the CIS & Ukraine (1) 135 1,010 Rest of the World 3,873 1,997 Total $ 86,946 $ 60,036 (1) In addition to Russia, the Company has IMAX Systems in the Commonwealth of Independent States ( “CIS”) which are Azerbaijan, Belarus, Kazakhstan, and Kyrgyzstan. Commencing in March 2022, in response to the ongoing conflict between Russia and Ukraine and resulting sanctions, the Company suspended its operations in Russia and Belarus. As of March 31, 2023, the IMAX network includes 54 systems in Russia, eight systems in Ukraine, and one system in Belarus. United States and Greater China each comprises greater than 10% of the Company’s total revenues for the three months ended March 31, 2023 and 2022 .

Employees Pension and Postretir

Employees Pension and Postretirement Benefits	3 Months Ended
	Mar. 31, 2023
Retirement Benefits [Abstract]
Employees Pension and Postretirement Benefits	14. Employee ’s Pension and Postretirement Benefits (a) Defined Benefit Plan The Company has an unfunded defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP” ), covering its CEO, Richard L. Gelfond. Under the terms of the SERP, if Mr. Gelfond ’s employment is terminated other than for cause (as defined in his employment agreement), he is entitled to receive SERP benefits in the form of a lump sum payment. SERP benefit payments to Mr. Gelfond are subject to a deferral for six months after the termination of his employment, at which time Mr. Gelfond will be entitled to receive interest on the deferred amount credited at the applicable federal rate for short-term obligations. Pursuant to an amendment to his employment agreement dated September 19, 2022, the term of Mr. Gelfond’ s employment was extended through December 31, 2025, although Mr. Gelfond has not informed the Company that he intends to retire at that time. Under the terms of his employment agreement, as amended, the total benefit payable to Mr. Gelfond under the SERP is fixed at $ 20.3 million. As of March 31, 2023, the Company's projected benefit obligation under the SERP is $ 17.5 million (December 31, 2022 — $ 17.3 million ). For the three months ended March 31, 2023 , the Company recorded interest costs of $ 0.2 million ( 2022 — less than $ 0.1 million) related to the SERP. The Company expects to recognize additional interest costs of $ 0.6 million related to the SERP during the remainder of 2023 . No contributions are expected to be made to the SERP in 2023. (b) Defined Contribution Pension Plan The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5 % of their base salary subject to certain prescribed maximums. During the three months ended March 31, 2023, the Company contributed and recorded expense of $ 0.3 million (2022 — $ 0.3 million) to its Canadian defined contribution plan and $ 0.3 million (2022 — $ 0.3 million) to its defined contribution employee plan under Section 401(k) of the U.S. Internal Revenue Code. (c) Postretirement Benefits – Executives The Company has an unfunded postretirement plan for Mr. Gelfond and Bradley J. Wechsler, former Chairman of the Company's Board of Directors (the “Executive Postretirement Benefit Plan”). The Executive Postretirement Benefit Plan provides that the Company will maintain health benefits for Messrs. Gelfond and Wechsler until they become eligible for Medicare and, thereafter, the Company will provide Medicare supplemental coverage as selected by Messrs. Gelfond and Wechsler. Mr. Wechsler retired from the Company’s Board of Directors on June 9, 2021. The Company maintained Mr. Wechsler’s health benefits through December 31, 2021, and thereafter is providing him with Medicare supplemental coverage or its cash equivalent. As of March 31, 2023, the Company’s postretirement benefits obligation under this plan is $ 0.5 million (December 31, 2022 — $ 0.5 million ). For the three months ended March 31, 2023, the Company has recorded an expense of less than $ 0.1 million (2022 — less than $ 0.1 million ) related to this plan. (d) Postretirement Benefits – Canadian Employees The Company has an unfunded postretirement plan for its Canadian employees meeting specific eligibility requirements. The Company will provide eligible participants, upon retirement, with health and welfare benefits. As of March 31, 2023, the Company’s postretirement benefits obligation under this plan is $ 0.9 million (December 31, 2022 — $ 1.0 million ). For the three months ended March 31, 2023, the Company has recorded expense of less than $ 0.1 million (2022 — less than $ 0.1 million ) related to this plan. (e) Deferred Compensation Benefit Plan The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if the executive incurred a separation from service from the Company (as defined therein). In 2018, the executive incurred a separation from service from the Company, and as such, the Retirement Plan benefits became fully vested as of December 31, 2018. As of March 31, 2023, the benefit obligation related to the Retirement Plan was $ 3.9 million (December 31, 2022 — $ 3.9 million ) and is recorded on the Company’s Condensed Consolidated Balance Sheets within Accrued and Other Liabilities. As the Retirement Plan is fully vested, the benefit obligation is measured at the present value of the benefits expected to be paid in the future with the accretion of interest recognized in the Condensed Consolidated Statements of Operations within Retirement Benefits Non-Service Expense. The Retirement Plan is funded by an investment in company-owned life insurance (“COLI”), which is recorded at its fair value on the Company’s Condensed Consolidated Balance Sheets within Prepaid Expenses. As of March 31, 2023, fair value of the COLI asset was $ 3.4 million (December 31, 2022 — $ 3.4 million ). Gains and losses resulting from changes in the cash surrender value of the COLI asset are recognized in the Condensed Consolidated Statements of Operations within Realized and Unrealized Investment Gains.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2023
Investments, All Other Investments [Abstract]
Financial Instruments	15. Financial Instruments (a) Financial Instruments The Company maintains cash with various major financial institutions. The Company’s cash is invested with highly rated financial institutions. The Company’s $ 99.2 million balance of cash and cash equivalents as of March 31, 2023 (December 31, 2022 — $ 97.4 million ) includes $ 83.6 million in cash held outside of Canada (December 31, 2022 — $ 79.7 million ), of which $ 47.2 million was held in the PRC (December 31, 2022 — $ 43.7 million ). (b) Fair Value Measurements The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of March 31, 2023 As of December 31, 2022 (In thousands of U.S. Dollars) Carrying Estimated Carrying Estimated Level 1 Cash and cash equivalents (1) $ 99,246 $ 99,246 $ 97,401 $ 97,401 Equity securities (2) 1,050 1,050 1,035 1,035 Level 2 Net financed sales receivables (3) $ 100,425 $ 96,801 $ 101,052 $ 100,059 Net investment in sales-type leases (3) 30,762 30,716 28,332 27,972 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,428 3,428 3,398 3,398 Foreign exchange contracts — designated forwards (2) ( 176 ) ( 176 ) ( 649 ) ( 649 ) Wells Fargo Credit Facility borrowings (1) ( 20,000 ) ( 20,000 ) ( 25,000 ) ( 25,000 ) HSBC China Facility borrowings (1) ( 12,165 ) ( 12,165 ) ( 12,496 ) ( 12,496 ) Bank of China Facility borrowings (1) ( 379 ) ( 379 ) ( 374 ) ( 374 ) Federal Economic Development Loan (3) ( 2,043 ) ( 2,043 ) ( 1,782 ) ( 1,782 ) Convertible Notes (5) ( 230,000 ) ( 218,210 ) ( 230,000 ) ( 196,717 ) Level 3 Interest in film classified as a financial instrument (6) $ — $ — $ — $ — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. (3) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data. (6) Recorded at amortized cost less impairment losses. Inputs used in the calculation of estimated fair value include management’s projection of future box office and ancillary receipts for the film net of distribution costs and other costs in accordance with the investment agreement. See 15(e) below. (c) Foreign Exchange Risk Management The Company is exposed to market risk from changes in foreign currency rates. A majority of the Company’s revenues is denominated in U.S. Dollars while a significant portion of its costs and expenses is denominated in Canadian Dollars. A portion of the Company’s net U.S. Dollar cash is converted to Canadian Dollars to fund Canadian Dollar expenses through the spot market. In China and Japan, the Company has ongoing operating expenses related to its operations in RMB and Japanese Yen, respectively. Net cash flows are converted to and from U.S. Dollars through the spot market. The Company also has cash receipts under leases denominated in RMB, Japanese Yen, Canadian Dollars and Euros which are converted to U.S. Dollars through the spot market. In addition, because IMAX films generate box office in 87 different countries, unfavorable exchange rates between applicable local currencies and the U.S. Dollar could have an impact on box-office receipts and the Company’s revenues and results of operations. The Company’s policy is to not use any financial instruments for trading or other speculative purposes. The Company has entered into a series of foreign currency forward contracts to manage the risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests as of March 31, 2023 (the “Foreign Currency Hedges”), with settlement dates throughout 2023 and 2024 . Foreign currency derivatives are recognized and measured in the Condensed Consolidated Balance Sheets at fair value. Changes in the fair value (i.e., gains or losses) are recognized in the Condensed Consolidated Statements of Operations except for derivatives designated and qualifying as foreign currency cash flow hedging instruments. The Company currently has cash flow hedging instruments associated with Selling, General and Administrative Expenses. For foreign currency cash flow hedging instruments related to Selling, General and Administrative Expenses, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in Accumulated Other Comprehensive (Loss) Income (“AOCI”) and reclassified to the Condensed Consolidated Statements of Operations when the forecasted transaction occurs. Any ineffective portion is recognized immediately in the Condensed Consolidated Statements of Operations. The notional value of foreign currency cash flow hedging instruments that qualify for hedge accounting as of March 31, 2023 was $ 34.4 million (December 31, 2022 — $ 24.7 million). The Company currently does not hold any derivatives which are not designated as hedging instruments. The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Condensed Consolidated Financial Statements: Fair value of derivatives in foreign exchange contracts : March 31, December 31, (In thousands of U.S. Dollars) Balance Sheet Location 2023 2022 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 193 $ 50 Accrued and other liabilities ( 369 ) ( 699 ) $ ( 176 ) $ ( 649 ) Derivatives in foreign currency hedging relationships are as follows : Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Foreign exchange contracts Derivative Gain — Forwards Recognized in OCI (Effective Portion) $ 134 $ 315 Location of Derivative Loss Reclassified from AOCI Three Months Ended March 31, (In thousands of U.S. Dollars) (Effective Portion) 2023 2022 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ ( 339 ) $ ( 29 ) The Company’s estimated net amount of the existing loss as of March 31, 2023 is $( 0.2 ) million , which is expected to be reclassified to the Condensed Consolidated Statements of Operations within the next twelve months. (d) Investments in Equity Securities The Company has an investment in the shares of an exchange traded fund which is classified as an equity investment. As of March 31, 2023, the value of the investment was $ 1.1 million (December 31, 2022 — $ 1.0 million ) and is recorded within Investment in Equity Securities in the Condensed Consolidated Balance Sheets. The Company held an investment in the preferred shares of enterprises which meets the criteria for classification as an equity security carried at historical cost, net of impairment charges. The carrying value of the equity security investment was $ 1.0 million as of March 31, 2023 (December 31, 2022 — $ 1.0 million ) and is recorded within Other Assets in the Condensed Consolidated Balance Sheets. (e) Interest in Film On January 10, 2022, IMAX (Shanghai) Culture and Technology Co., Ltd, a wholly-owned subsidiary of IMAX China, entered into a joint film investment agreement with Wanda Film (Horgos) Co. Ltd. to invest RMB 30.0 million ($ 4.7 million) in the movie Mozart from Space , which was released on July 15, 2022. Pursuant to the investment agreement, IMAX (Shanghai) Culture and Technology Co., Ltd. has the right to receive a share of the profits or losses of the film distribution. IMAX (Shanghai) Culture and Technology Co., Ltd.’s commitment is limited to its investment and has no further obligation if the actual movie production cost exceeds the original budget. The investment meets the criteria for classification as a financial asset. The investment is measured at amortized cost less impairment losses and is recorded within Other Assets in the Condensed Consolidated Balance Sheets. During the second quarter of 2022 , the Company recognized a full impairment of its RMB 30.0 million ($ 4.5 million) investment in Mozart from Space based on projected box office results and distribution costs.

Executive Transition Costs

Executive Transition Costs	3 Months Ended
	Mar. 31, 2023
Executive Transition Costs [Abstract]
Executive Transition Costs	16. Executive Transition Costs On March 13, 2023, the Company and Megan Colligan, President, IMAX Entertainment and Executive Vice President of the Company agreed to conclude Ms. Colligan’s employment with the Company, effective April 30, 2023 . Pursuant to the employment agreement between the Company and Ms. Colligan, dated as of October 10, 2018, and the letter agreement between the Company and Ms. Colligan, dated as of March 15, 2023, the Company recognized executive transition costs of $ 1.4 million associated with the departure of Ms. Colligan during the first quarter of 2023. The costs include severance of $ 1.6 million, transition services covering three months of $ 0.8 million, and the reversal of previously recognized share-based compensation costs of $ 1.0 million for PSU forfeitures.

Non-Controlling Interests

Non-Controlling Interests	3 Months Ended
	Mar. 31, 2023
Temporary Equity Disclosure [Abstract]
Non-Controlling Interests	17. Non-Controlling Interests (a) IMAX China Non-Controlling Interest The Company indirectly owns 71.63 % of IMAX China, whose shares trade on the Hong Kong Stock Exchange (December 31, 2022 — 71.73 %). IMAX China remains a consolidated subsidiary of the Company. As of March 31, 2023, the balance of the Company’s non-controlling interest in IMAX China is $ 69.1 million (December 31, 2022 — $ 65.7 million). For the three months ended March 31, 2023, the net income attributable to the non-controlling interest in IMAX China was $ 2.7 million (2022 — $ 1.7 million ). (b) Other Non-Controlling Interest The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $ 25.0 million, with the possibility of contributing additional funds. The Company has contributed $ 9.0 million to the Original Film Fund since 2014 and has reached its maximum contribution. As of March 31, 2023, the Original Film Fund has invested $ 22.3 million toward the development of original films. The related production, financing and distribution agreement includes put and call rights relating to change of control of the rights, title and interest in the co-financed pictures. (c) Non-Controlling Interest in Temporary Equity The following table summarizes the movement of the non-controlling interest in temporary equity related to the Original Film Fund for the three months ended March 31, 2023 and 2022: March 31, (In thousands of U.S. Dollars) 2023 2022 Beginning balance $ 722 $ 758 Net income 9 3 Ending balance $ 731 $ 761

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Principles	Accounting Principles IMAX Corporation, together with its consolidated subsidiaries (the “Company” or “IMAX”), prepares its financial statements in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the Company’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments of a normal recurring nature that are necessary for a fair statement of the results for the interim periods presented. The Condensed Consolidated Balance Sheet at December 31, 2022 was derived from the Company’s audited annual Consolidated Financial Statements, but does not contain all of the footnote disclosures included in the annual financial statements. The interim results presented in the Company’s Condensed Consolidated Statements of Operations are not necessarily indicative of results for a full year. These Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements included in the Company’s 2022 Annual Report on Form 10-K (the “2022 Form 10-K”), which should be consulted for a summary of the significant accounting policies utilized by the Company. The Condensed Consolidated Financial Statements are prepared following the same accounting policies disclosed in the 2022 Form 10-K. As disclosed in Note 13 to the Condensed Consolidated Financial Statements, in the first quarter of 2023, the Company revised its reportable segments.
Principles of Consolidation	Principles of Consolidation These Condensed Consolidated Financial Statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions have been eliminated. The Company has evaluated its various variable interests to determine whether they are VIEs as required by U.S. GAAP. The Company has interests in ten film production companies, which have been identified as VIEs. The Company is the primary beneficiary of and consolidates five of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant. The majority of the assets relating to these production companies are held by the IMAX Original Film Fund (the “Original Film Fund”) as described in Note 17 (b). The Company does not consolidate the other five film production companies because it does not have the power to direct their activities and it does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Condensed Consolidated Financial Statements. A loss in the value of an equity method investment that is other than temporary is recognized as a charge in the Condensed Consolidated Statement of Operations. As of March 31, 2023 and December 31, 2022, total assets and liabilities of the Company’s consolidated VIEs are as follows: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Total assets $ 1,537 $ 1,523 Total liabilities $ 248 $ 248
Estimates and Assumptions	Estimates and Assumptions In preparing the Company’s Condensed Consolidated Financial Statements, management makes judgments in applying various accounting policies. The areas of policy judgment are consistent with those reported in Note 3(b) of the Company’s audited Consolidated Financial Statements included in its 2022 Form 10-K. Management also considers that its determination of operating and reporting segments represents an area of judgment, and has made this conclusion on the basis of what comprises the discrete financial information produced, but not provided to or used by its Chief Operating Decision Maker (“CODM”) to carry out this function. In addition, management makes assumptions about the Company’s future operating results and cash flows in deriving critical accounting estimates used in preparing the Condensed Consolidated Financial Statements. The significant estimates made by management include, but are not limited to: (i) the allocation of the transaction price in an IMAX System arrangement to distinct performance obligations; (ii) the amount of variable consideration to be earned on sales of IMAX Systems based on projections of future box office performance; (iii) expected credit losses on accounts receivable, financing receivables, and variable consideration receivables; (iv) provisions for the write-down of excess and obsolete inventory; (v) the fair values of the reporting units used in assessing the recoverability of goodwill; (vi) the cash flow projections used in testing the recoverability of long-lived assets such as the system equipment supporting joint revenue sharing arrangements; (vii) the economic lives of the system equipment supporting joint revenue sharing arrangements; (viii) the useful lives of intangible assets; (ix) the ultimate revenue forecasts used to test the recoverability of film assets; (x) the discount rates used to determine the present value of financing receivables and lease liabilities, as well as to determine the fair values of the Company’s reporting units for the purpose of assessing the recoverability of goodwill; (xi) pension plan assumptions; (xii) estimates related to the fair value and projected vesting of share-based payment awards; (xiii) the valuation of deferred income tax assets; and (xiv) reserves related to uncertain tax positions.
Recently Issued Accounting Standards Not Yet Adopted	Adoption of New Accounting Policies In March 2022, the FASB issued ASU No. 2022-02, “2022-02: Financial Instruments — Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures” (“ASU 2022-02” ). ASU 2022-02 amends and eliminates the accounting guidance for Troubled Debt Restructurings by creditors, while enhancing disclosure requirements for certain loan refinancings and restructurings by creditors when a borrower is experiencing financial difficulty and requires for public business entities, to disclose current-period gross write offs by year of origination for financing receivables and net investments in leases. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2022-02 for the period ended March 31, 2023. The adoption of ASU 2022-02 did no t have a material impact on the Company's Condensed Consolidated Financial Statements. In September 2022, the FASB issued ASU No. 2022-04, “2022-04: Liabilities — Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations” (“ASU 2022-04” ). ASU 2022-04 requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program's nature, activity during the period, changes from period to period, and potential magnitude. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2022-04 for the period ended March 31, 2023 . The adoption of ASU 2022-04 did no t have a material impact on the Company's Condensed Consolidated Financial Statements. Recently Issued FASB Accounting Standard Codification Updates Not Yet Adopted The Company considers the applicability and impact of all FASB ASUs that are recently issued, but not yet effective. ASUs that are not noted above were assessed and determined to be not applicable or not significant to the Company’s Condensed Consolidated Financial Statements for the period ended March 31, 2023 .
Credit Risk	The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are received on a regular basis. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears, and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category, but are not in as good condition as the receivables in the Credit Watch category. In certain situations, a theater operator may be placed on nonaccrual status and all revenue recognition related to the theater may be suspended, including the accretion of Finance Income for Financing Receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are suspended, including the accretion of Finance Income for Financing Receivables. During the period when the accretion of Finance Income is suspended for Financing Receivables, any payments received from a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a reversal of the provision is recorded to the extent of the residual cash received. Once the collectability issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of Finance Income. When a customer’s aging exceeds 90 days, the Company’s policy is to perform an enhanced review to assess collectability of the theater’s past due accounts. The over 90 days past due category may be an indicator of potential impairment as up to 90 days outstanding is considered to be a reasonable time to resolve any issues. The Company develops an estimate of expected credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates, which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after considering management’s internal credit quality classifications. Additional credit loss provisions are also recorded taking into account macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management. Commencing in March 2022, in response to numerous sanctions imposed by the United States, Canada and the European Union on companies transacting in Russia and Belarus resulting from ongoing conflict between Russia and Ukraine, the Company suspended its operations in Russia and Belarus. In the first quarter of 2022, the Company recorded provisions for potential credit losses against substantially all of its receivables in Russia due to uncertainties associated with the ongoing conflict and resulting sanctions. These receivables relate to existing sale agreements as the Company is not party to any joint revenue sharing arrangements in these countries. In addition, beginning in the first quarter of 2022, exhibitors in Russia, Ukraine, and Belarus were placed on nonaccrual status for maintenance revenue and finance income. As of March 31, 2023, all IMAX Systems in Ukraine have reopened. The Company continues to closely monitor the evolving impacts of this conflict (including the sanctions imposed by the United States, Canada and the European Union) and its effects on the global economy and the Company. On September 7, 2022, Cineworld, the parent company of Regal, and certain of its subsidiaries and Regal CineMedia Holdings, LLC, filed petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in the Southern District of Texas. The Company had an unsecured pre-petition claim of $ 11.4 million related to receivables from the entities included in the reorganization proceedings. On October 21, 2022, the Company was ratified by the bankruptcy court as a critical vendor of Cineworld, allowing the Company to collect pre-petition amounts owed to it by Cineworld, and requiring Cineworld to stay current on the Company’s post-petition receivables. On November 8, 2022, IMAX Corporation entered into a trade agreement with Cineworld (the “Trade Agreement”), pursuant to which Cineworld affirmed its pre-petition obligations to the Company and its post-petition obligations to the Company during the Chapter 11 proceedings, the amount of the receivables owed to the Company and agreed to a payment plan under which all amounts due will be settled over the period from November 9, 2022 to April 12, 2023. As of April 17, 2023, the Company had received all of the payments due from Cineworld in accordance with the terms of the Trade Agreement with respect to the pre-petition obligations. Based on its evaluation of its contracts with Cineworld, its assessment of the reorganization and its discussions with Cineworld to date, the Company has determined that no additional provision for expected credit losses is required. The Company also does not expect to see a material impact on its IMAX network with Cineworld resulting from this reorganization. There can, however, be no guarantees as to the ultimate outcome of a Chapter 11 proceeding. Management’s judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. As a result, the Company’s judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect. The impacts of inflation, and rising interest rates may impact future credit losses. The Company will continue to monitor economic trends and conditions and portfolio performance and adjust its allowance for credit loss accordingly. Accounts Receivable Accounts receivable principally includes amounts currently due to the Company under IMAX System sale and sales-type lease arrangements, contingent fees owed by theater operators as a result of box office performance, and fees for maintenance services. Accounts receivable also includes amounts due to the Company from movie studios and other content creators principally for digitally remastering films into IMAX formats, as well as for film distribution and post-production services.
Lessee Leases	(a) IMAX Corporation as a Lessee The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term. Most of the Company’s leases include one or more options to renew, with renewal terms that can extend the lease term from one to five years or more. The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs and its level of investment in leasehold improvements, among other factors. The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property. None of the Company’s leases include options to purchase the leased property. The depreciable lives of right-of-use assets and related leasehold improvements are limited by the expected lease term. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed. In the second quarter of 2022, the Company entered into a finance lease arrangement involving equipment used to facilitate the delivery of live events to certain IMAX locations. The lease arrangement includes an option for the Company to purchase the equipment at the end of the lease term that is reasonably certain to be exercised. The resulting right-of-use assets are being depreciated from the lease commencement dates over the useful life of the underlying equipment. The incremental borrowing rate used in the calculation of the lease liabilities is based on the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar term.
Lessor Leases	(b) IMAX Corporation as a Lessor The Company provides IMAX Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system. The customer’s rights under the Company’s sales-type lease arrangements are described in Note 3(o) of the Company’s audited Consolidated Financial Statements included in its 2022 Form 10-K. Under the Company’s sales-type lease arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s lease portfolio terms are typically non-cancellable for 10 years or longer with renewal provisions from inception. The Company’s sales-type lease arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty generally after the first year of the lease until the end of the lease term. The customer is responsible for obtaining insurance coverage for the IMAX System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX System is returned to the Company. The Company also provides IMAX Systems to customers through joint revenue sharing arrangements. Under the traditional form of these arrangements, in exchange for providing the IMAX System under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than requiring the customer to pay a fixed upfront fee or annual minimum payments. Under certain other joint revenue sharing arrangements, known as hybrid arrangements, the customer is responsible for making fixed upfront payments prior to the delivery and installation of the IMAX System. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to the IMAX System under a joint revenue sharing arrangement generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX System is returned to the Company. The following lease payments are expected to be received by the Company for its sales-type leases and joint revenue sharing arrangements in each of the next five years and thereafter following the March 31, 2023 balance sheet date: Sales-Type Joint Revenue (In thousands of U.S. Dollars) Leases Sharing Arrangements 2023 (nine months remaining) $ 2,260 $ 130 2024 3,519 69 2025 3,248 27 2026 3,163 — 2027 3,018 — Thereafter 16,889 — Total $ 32,097 $ 226
Commitments and Contingencies	The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company records a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management’s judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred.
Segment Reporting	The Company has the following reportable segments: (i) Content Solutions, which principally includes the digital remastering of films and other content into IMAX formats for distribution to the IMAX network. To a lesser extent, the Content Solutions segment also earns revenue from the distribution of large-format documentary films and exclusive experiences ranging from live performances to interactive events with leading artists and creators, as well as film post-production services. (ii) Technology Products and Services, which includes results from the sale or lease of IMAX Systems, as well as from the maintenance of IMAX Systems. To a lesser extent, the Technology Product and Services segment also earns revenue from certain ancillary theater business activities, including after-market sales of IMAX System parts and 3D glasses.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
VIEs Total Assets and Liabilities	As of March 31, 2023 and December 31, 2022, total assets and liabilities of the Company’s consolidated VIEs are as follows: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Total assets $ 1,537 $ 1,523 Total liabilities $ 248 $ 248

Receivables (Tables)

Receivables (Tables)	3 Months Ended
	Mar. 31, 2023
Receivables [Abstract]
Summary of Allowance For Credit Losses Related to Accounts Receivable	The following tables summarize the activity in the allowance for credit losses related to Accounts Receivable for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 (In thousands of U.S. Dollars) Theater Studios Other Total Beginning balance $ 11,144 $ 1,699 $ 1,276 $ 14,119 Current period (reversal) provision, net ( 265 ) 3 21 ( 241 ) Write-offs ( 115 ) — — ( 115 ) Foreign exchange 60 5 — 65 Ending balance $ 10,824 $ 1,707 $ 1,297 $ 13,828 Three Months Ended March 31, 2022 (In thousands of U.S. Dollars) Theater Studios Other Total Beginning balance $ 8,867 $ 1,994 $ 1,085 $ 11,946 Current period provision, net 1,981 3 273 2,257 Write-offs — — — — Foreign exchange ( 17 ) ( 2 ) — ( 19 ) Ending balance $ 10,831 $ 1,995 $ 1,358 $ 14,184
Schedule of Financing Receivables	As of March 31, 2023 and December 31, 2022, financing receivables consist of the following: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Net investment in leases Gross minimum payments due under sales-type leases $ 32,097 $ 29,727 Unearned finance income ( 557 ) ( 619 ) Present value of minimum payments due under sales-type leases 31,540 29,108 Allowance for credit losses ( 778 ) ( 776 ) Net investment in leases 30,762 28,332 Financed sales receivables Gross minimum payments due under financed sales 141,119 141,337 Unearned finance income ( 29,161 ) ( 29,340 ) Present value of minimum payments due under financed sales 111,958 111,997 Allowance for credit losses ( 11,533 ) ( 10,945 ) Net financed sales receivables 100,425 101,052 Total financing receivables $ 131,187 $ 129,384 Net financed sales receivables due within one year $ 33,721 $ 32,366 Net financed sales receivables due after one year 66,704 68,686 Total financed sales receivables $ 100,425 $ 101,052
Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate	As of March 31, 2023 and December 31, 2022, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: March 31, December 31, 2023 2022 Weighted-average remaining lease term (in years) Sales-type lease arrangements 8.9 9.0 Weighted-average interest rate Sales-type lease arrangements 8.25 % 8.23 % Financed sales receivables 8.85 % 8.79 %
Schedule of Net Investment In Leases by Credit Quality Indicator	The tables below provide information on the Company’s net investment in leases by credit quality indicator as of March 31, 2023 and December 31, 2022. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of March 31, 2023 2023 2022 2021 2020 2019 Prior Total Net investment in leases: Credit quality classification: In good standing $ 2,200 $ 4,141 $ 7,017 $ 2,544 $ 2,020 $ 1,020 $ 18,942 Credit Watch — — — — — — — Pre-approved transactions — — 3,112 1,179 5,423 2,483 12,197 Transactions suspended — — — — — 401 401 Total net investment in leases $ 2,200 $ 4,141 $ 10,129 $ 3,723 $ 7,443 $ 3,904 $ 31,540 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2022 2022 2021 2020 2019 2018 Prior Total Net investment in leases: Credit quality classification: In good standing $ 4,148 $ 6,969 $ 2,494 $ 1,977 $ — $ 1,016 $ 16,604 Credit Watch — — — — — — — Pre-approved transactions — 3,089 1,162 5,401 2,451 — 12,103 Transactions suspended — — — — — 401 401 Total net investment in leases $ 4,148 $ 10,058 $ 3,656 $ 7,378 $ 2,451 $ 1,417 $ 29,108
Schedule of Financed Sale Receivables by Credit Quality Indicator	The tables below provide information on the Company’s financed sale receivables by credit quality indicator as of March 31, 2023 and December 31, 2022. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of March 31, 2023 2023 2022 2021 2020 2019 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 2,163 $ 9,830 $ 8,617 $ 6,381 $ 8,149 $ 45,647 $ 80,787 Credit Watch — 1 — — — 943 944 Pre-approved transactions — — 2,377 1,162 1,590 13,220 18,349 Transactions suspended — 272 795 142 1,256 9,413 11,878 Total financed sales receivables $ 2,163 $ 10,103 $ 11,789 $ 7,685 $ 10,995 $ 69,223 $ 111,958 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2022 2022 2021 2020 2019 2018 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 10,252 $ 8,643 $ 6,280 $ 8,541 $ 9,854 $ 39,912 $ 83,482 Credit Watch — — — — — 1,152 1,152 Pre-approved transactions — 2,318 1,399 1,134 1,449 9,243 15,543 Transactions suspended 272 664 142 1,269 1,197 8,276 11,820 Total financed sales receivables $ 10,524 $ 11,625 $ 7,821 $ 10,944 $ 12,500 $ 58,583 $ 111,997
Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables	The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as of March 31, 2023 and December 31, 2022: As of March 31, 2023 (In thousands of U.S. Dollars) Accrued 30-89 90+ Billed Unbilled Recorded Allowance Net Net investment in leases $ 235 $ 433 $ 2,892 $ 3,560 $ 27,980 $ 31,540 $ ( 778 ) $ 30,762 Financed sales receivables 1,352 3,190 13,131 17,673 94,285 $ 111,958 ( 11,533 ) 100,425 Total $ 1,587 $ 3,623 $ 16,023 $ 21,233 $ 122,265 $ 143,498 $ ( 12,311 ) $ 131,187 As of December 31, 2022 (In thousands of U.S. Dollars) Accrued 30-89 90+ Billed Unbilled Recorded Allowance Net Net investment in leases $ 237 $ 216 $ 2,593 $ 3,046 $ 26,062 $ 29,108 $ ( 776 ) $ 28,332 Financed sales receivables 2,269 1,307 12,793 16,369 95,628 111,997 ( 10,945 ) 101,052 Total $ 2,506 $ 1,523 $ 15,386 $ 19,415 $ 121,690 $ 141,105 $ ( 11,721 ) $ 129,384
Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income	The following tables provide information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as of March 31, 2023 and December 31, 2022. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. As of March 31, 2023 (In thousands of U.S. Dollars) Accrued 30-89 Days 90+ Days Billed Unbilled Allowance Net Net investment in leases $ 220 $ 387 $ 2,892 $ 3,499 $ 18,286 $ ( 228 ) $ 21,557 Financed sales receivables 940 2,356 10,445 13,741 42,785 ( 1,460 ) 55,066 Total $ 1,160 $ 2,743 $ 13,337 $ 17,240 $ 61,071 $ ( 1,688 ) $ 76,623 As of December 31, 2022 (In thousands of U.S. Dollars) Accrued 30-89 Days 90+ Days Billed Unbilled Allowance Net Net investment in leases $ 190 $ 181 $ 2,593 $ 2,964 $ 17,070 $ ( 230 ) $ 19,804 Financed sales receivables 1,550 1,115 10,814 13,479 43,172 ( 1,587 ) 55,064 Total $ 1,740 $ 1,296 $ 13,407 $ 16,443 $ 60,242 $ ( 1,817 ) $ 74,868
Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status	The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as of March 31, 2023 and December 31, 2022: As of March 31, 2023 As of December 31, 2022 (In thousands of U.S. Dollars) Recorded Allowance Net Recorded Allowance Net Net investment in leases $ 401 $ ( 401 ) $ — $ 401 $ ( 401 ) $ — Net financed sales receivables 20,461 ( 7,599 ) 12,862 27,364 ( 9,589 ) 17,775 Total $ 20,862 $ ( 8,000 ) $ 12,862 $ 27,765 $ ( 9,990 ) $ 17,775
Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables	The following tables summarize the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 Net Investment Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 776 $ 10,945 Current period (reversal) provision, net ( 2 ) 549 Write-offs — — Foreign exchange 4 39 Ending balance $ 778 $ 11,533 Three Months Ended March 31, 2022 Net Investment Net Financed (In thousands of U.S. Dollars) in Leases Sales Receivables Beginning balance $ 798 $ 5,414 Current period (reversal) provision, net ( 93 ) 5,708 Write-offs — — Foreign exchange 1 13 Ending balance $ 706 $ 11,135
Summary of Allowance For Credit Losses Related to Variable Consideration Receivables	The following table summarizes the activity in the Allowance for Credit Losses related to Variable Consideration Receivables for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 2022 (In thousands of U.S. Dollars) Theater Theater Beginning balance $ 610 $ 1,082 Current period reversal, net ( 86 ) ( 643 ) Foreign exchange 2 — Ending balance $ 526 $ 439

Lease Arrangements (Tables)

Lease Arrangements (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Components of Operating Lease Expense	For the three months ended March 31, 2023 and 2022, the components of lease expense recorded within Selling, General and Administrative Expenses are as follows: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Operating lease cost: Amortization of operating lease assets $ 151 $ 693 Interest on operating lease liabilities 724 215 Short-term and variable lease costs 204 160 Finance lease cost: Amortization of finance lease assets 100 N/A Interest on finance lease liabilities 14 N/A Total lease cost $ 1,193 $ 1,068
Supplemental Cash and Non-Cash Flow Information Related to Leases	For the three months ended March 31, 2023 and 2022, supplemental cash and non-cash information related to leases is as follows: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating leases $ 971 $ 945 Finance leases $ — N/A Supplemental disclosure of noncash leasing activities: Right-of-use assets obtained in exchange for operating lease obligations $ 228 $ 217 Right-of-use assets obtained in exchange for finance lease obligations $ — N/A
Lessee Operating Lease Balance Sheet Amounts and Lines	As of March 31, 2023 and December 31, 2022, supplemental balance sheet information related to leases is as follows: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Assets Balance Sheet Location Operating lease right-of-use assets Property, plant and equipment $ 11,888 $ 12,341 Finance lease right-of-use assets Property, plant and equipment $ 1,776 $ 1,876 Liabilities Balance Sheet Location Operating lease liabilities Accrued and other liabilities $ 14,140 $ 14,461 Finance lease liabilities (1) Accrued and other liabilities $ 967 $ 1,011 (1) Recorded net of a $ 0.9 million upfront payment made upon execution of the finance lease arrangement.
Lessee Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate	As of March 31, 2023 and December 31, 2022, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s leases are as follows: March 31, December 31, 2023 2022 Operating leases: Weighted-average remaining lease term (years) 5.8 6.0 Weighted-average discount rate 5.91 % 5.90 % Finance leases: Weighted-average remaining lease term (years) 4.4 4.7 Weighted-average discount rate 6.00 % 6.00 %
Lessee Operating and Finance Lease, Maturity	As of March 31, 2023, the maturities of the Company’s operating and finance lease liabilities are as follows: (In thousands of U.S. Dollars) Operating Leases Finance Leases 2023 (nine months remaining) $ 2,699 $ 508 2024 3,049 508 2025 2,457 — 2026 2,069 — 2027 2,093 — Thereafter 4,354 — Total lease payments $ 16,721 $ 1,016 Less: interest expense ( 2,581 ) ( 49 ) Present value of lease liabilities $ 14,140 $ 967
Schedule of Maturities of Lease Receivables	The following lease payments are expected to be received by the Company for its sales-type leases and joint revenue sharing arrangements in each of the next five years and thereafter following the March 31, 2023 balance sheet date: Sales-Type Joint Revenue (In thousands of U.S. Dollars) Leases Sharing Arrangements 2023 (nine months remaining) $ 2,260 $ 130 2024 3,519 69 2025 3,248 27 2026 3,163 — 2027 3,018 — Thereafter 16,889 — Total $ 32,097 $ 226

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventories	As of March 31, 2023 and December 31, 2022, Inventories consist of the following: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Raw materials $ 29,554 $ 25,365 Work-in-process 2,220 2,034 Finished goods 5,718 4,135 $ 37,492 $ 31,534

Borrowings (Tables)

Borrowings (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Revolving Credit Facility Borrowings	As of March 31, 2023 and December 31, 2022, Revolving Credit Facility Borrowings, Net includes the following: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Wells Fargo Credit Facility borrowings $ 20,000 $ 25,000 HSBC China Facility borrowings 12,165 12,496 Bank of China Facility borrowings 379 374 Unamortized debt issuance costs ( 1,519 ) ( 1,759 ) Revolving Credit Facility Borrowings, net $ 31,025 $ 36,111
Summary of Convertible Notes, Net	As of March 31, 2023 and December 31, 2022, Convertible Notes and Other Borrowings, Net includes the following: March 31, December 31, (In thousands of U.S. Dollars) 2023 2022 Convertible Notes $ 230,000 $ 230,000 Unamortized discounts and debt issuance costs ( 4,494 ) ( 4,870 ) Convertible Notes, net 225,506 225,130 Federal Economic Development Loan 3,128 2,812 Unaccreted interest benefit ( 1,085 ) ( 1,030 ) Federal Economic Development Loan, net 2,043 1,782 Convertible Notes and Other Borrowings, net $ 227,549 $ 226,912

Condensed Consolidated Statem_7

Condensed Consolidated Statements of Operations Supplemental Information (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Selling Expenses, Including Sales Commissions and Marketing and Other Expenses	The following table summarizes the Company’s selling expenses, including sales commissions and marketing and other, which are recognized within Costs and Expenses Applicable to Revenues in the Condensed Consolidated Statements of Operations, for three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 2022 (In thousands of U.S. Dollars) Sales Marketing Sales Marketing Technology sales (1) $ 200 $ 16 $ — $ 162 Image enhancement and maintenance services (2) — 6,772 — 2,915 Technology rentals (3) 73 260 45 465 Total $ 273 $ 7,048 $ 45 $ 3,542 (1) Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred. (2) Film exploitation costs, including advertising and marketing costs, are expensed as incurred. (3) Sales commissions related to joint revenue sharing arrangements accounted for operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed. Direct advertising and marketing costs for each IMAX System are expensed as incurred.

Condensed Consolidated Statem_8

Condensed Consolidated Statements of Cash Flows Supplemental Information (Tables)	3 Months Ended
	Mar. 31, 2023
Supplemental Cash Flow Elements [Abstract]
Summary of Changes in Other Operating Assets and Liabilities	Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 (Increase) decrease in: Financing receivables $ ( 1,625 ) $ 3,916 Prepaid expenses ( 2,406 ) ( 2,413 ) Variable consideration receivables ( 3,440 ) 829 Other assets 80 209 Increase (decrease) in: Accounts payable 513 2,184 Accrued and other liabilities ( 1,466 ) ( 14,911 ) $ ( 8,344 ) $ ( 10,186 )
Summary of Depreciation and Amortization	Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Film assets $ 3,452 $ 3,178 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements 5,772 5,548 Other property, plant and equipment (1) 2,287 2,028 Other intangible assets (2) 1,399 1,532 Other assets (3) 410 455 $ 13,320 $ 12,741 (1) Includes the amortization of laser projection systems, camera, and lens upgrades recorded in Research and Development on the Condensed Consolidated Statement of Operations of $ 0.1 million in the three months ended March 31, 2023 (2022 — $ 0.2 million ). (2) Includes the amortization of licenses and intellectual property recorded in Research and Development on the Condensed Consolidated Statement of Operations of $ 0.3 million in the three months ended March 31, 2023 (2022 — $ 0.3 million ). (3) Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements.
Write Downs, Net of Recoveries	Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements (1) $ 297 $ 202 Other property, plant and equipment 1 2 Inventories 6 12 Film assets — 165 $ 304 $ 381 (1) In the three months ended March 31, 2023, the Company recorded charges of $ 0.3 million (2022 — $ 0.2 million ) in Costs and Expenses Applicable to Revenues ― Technology Rentals mostly related to the write-down of leased xenon-based digital systems which were taken out of service in connection with customer upgrades to laser-based digital systems, as well as the closure of one IMAX System.
Significant Non-cash Investing Activities	Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Net (decrease) increase in accruals related to: Investment in equipment supporting joint revenue sharing arrangements $ ( 764 ) $ 1,133 Acquisition of other intangible assets ( 22 ) 32 Purchases of property, plant and equipment 548 — $ ( 238 ) $ 1,165

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Effective Tax Rates	For the three months ended March 31, 2023, the Company recorded income tax expense of $ 4.9 million (2022 — $ 2.6 million ). For the three months ended March 31, 2023, the Company’s effective tax rate differs from the combined Canadian federal and provincial statutory income tax rate due to the following factors: Three Months Ended Three Months Ended March 31, 2023 March 31, 2022 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Income tax (expense) benefit at combined statutory rates $ ( 2,652 ) 26.5 % $ 2,475 26.5 % Adjustments resulting from: Increase in valuation allowance ( 1,610 ) 16.1 % ( 5,009 ) ( 53.6 %) Shortfall tax benefits related to share-based compensation ( 83 ) 0.8 % ( 129 ) ( 1.4 %) Changes to tax reserves ( 258 ) 2.6 % ( 160 ) ( 1.7 %) Other ( 282 ) 2.8 % 213 2.3 % Income tax expense $ ( 4,885 ) 48.8 % $ ( 2,610 ) ( 27.9 %)
Income Tax Expense in Other Comprehensive Income	For the three months ended March 31, 2023 and 2022, the Income Tax Expense related to the components of Other Comprehensive Income (“OCI”) is as follows: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Unrealized change in cash flow hedging instruments $ ( 35 ) $ ( 82 ) Realized change in cash flow hedging instruments ( 89 ) ( 8 ) Defined benefit and postretirement benefit plans 46 ( 12 ) $ ( 78 ) $ ( 102 )

Capital Stock and Reserves (Tab

Capital Stock and Reserves (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stock Compensation	For the three months ended March 31, 2023, share-based compensation expense totaled $ 5.1 million (2022 — $ 6.1 million ) and is reflected in the following accounts in the Condensed Consolidated Statements of Operations: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Costs and expenses applicable to revenues $ 263 $ 239 Selling, general and administrative expenses 5,196 5,726 Research and development 99 87 Executive transition costs ( 499 ) — $ 5,059 $ 6,052
Stock-based Compensation by Plan Type	The following table summarizes the Company’s share-based compensation expense by each award type: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Stock Options $ 84 $ 207 Restricted Share Units 3,365 3,411 Performance Stock Units 924 1,729 IMAX China Stock Options 10 34 IMAX China Long Term Incentive Plan Restricted Share Units 541 497 IMAX China Long Term Incentive Plan Performance Stock Units 135 174 $ 5,059 $ 6,052
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes the activity under the Company’s Stock Option Plan (“SOP”) and the IMAX Corporation Second Amended and Restated Long-Term Incentive Plan (as may be amended, “IMAX LTIP”) for the three months ended March 31, 2023 and 2022: Number of Shares Weighted Average Exercise 2023 2022 2023 2022 Stock options outstanding, beginning of period 3,604,739 3,736,157 $ 26.36 $ 26.61 Granted — — — — Exercised — — — — Forfeited — — — — Expired ( 144,366 ) ( 126,569 ) 31.85 33.61 Cancelled — ( 2,197 ) — 32.50 Stock options outstanding, end of period 3,460,373 3,607,391 26.13 26.36 Stock options exercisable, end of period 3,460,373 3,524,298 26.13 26.45
Restricted Stock Units Activity under the IMAX LTIP	The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the three months ended March 31, 2023 and 2022: Number of Awards Weighted Average Grant Date 2023 2022 2023 2022 RSUs outstanding, beginning of period 1,252,044 1,457,883 $ 19.16 $ 19.16 Granted 811,529 636,427 17.73 19.64 Vested and settled ( 677,611 ) ( 648,527 ) 18.70 18.78 Forfeited ( 19,509 ) ( 1,328 ) 19.80 14.84 RSUs outstanding, end of period 1,366,453 1,444,455 18.53 19.54 IMAX LTIP
Performance Stock Units Activity under the IMAX LTIP	The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP for the three months ended March 31, 2023 and 2022: Number of Awards Weighted Average Grant Date 2023 2022 2023 2022 PSUs outstanding, beginning of period 931,716 613,405 $ 18.96 $ 18.21 Granted (1) 580,118 359,138 17.68 20.34 Forfeited ( 208,648 ) — 18.09 — Vested and settled (1) ( 368,602 ) — 16.92 — PSUs outstanding, end of period 934,584 972,543 19.16 19.00 (1) For the three months ended March 31, 2023 , the balance of shares granted includes 157,963 additional shares, at a weighted average grant date fair value per share of $ 16.92 , as PSUs granted in 2020 with EBITDA-based targets vested at 175 % on account of full achievement of the targets. This performance adjustment in the first quarter of 2023 reflects the Company's performance assessment of its first PSU awards.
Basic and Diluted Per-share Computations	The following table reconciles the denominator of the basic and diluted weighted average share computations: Three Months Ended March 31, 2023 2022 (In thousands) Issued and outstanding, beginning of period 54,149 58,654 Weighted average number of shares repurchased, net ( 85 ) ( 80 ) Weighted average number of shares outstanding - basic 54,064 58,574 Weighted average effect of potential common shares, if dilutive 927 — Weighted average number of shares outstanding - diluted 54,991 58,574

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue by Segment	The following tables summarize the Company’s Revenues by reportable segment and revenue stream type for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, 2023 (In thousands of U.S. Dollars) Technology Sales Image Enhancement Technology Rentals Finance Income Total Content Solutions Segment Film Remastering and Distribution $ — $ 30,073 $ — $ — $ 30,073 Other Content Solutions — 2,028 — — 2,028 — 32,101 — — 32,101 Technology Products and Services Segment System Sales 16,119 — — — 16,119 System Rentals — — 20,058 — 20,058 Maintenance — 13,551 — — 13,551 Finance Income — — — 1,939 1,939 16,119 13,551 20,058 1,939 51,667 Sub-total for reportable segments 16,119 45,652 20,058 1,939 83,768 All Other 1,703 1,475 — — 3,178 Total $ 17,822 $ 47,127 $ 20,058 $ 1,939 $ 86,946 Three Months Ended March 31, 2022 (In thousands of U.S. Dollars) Technology Sales Image Enhancement and Maintenance Services Technology Rentals Finance Income Total Content Solutions Segment Film Remastering and Distribution $ — $ 19,564 $ — $ — $ 19,564 Other Content Solutions — 1,406 18 — 1,424 — 20,970 18 — 20,988 Technology Products and Services Segment System Sales 7,973 — — — 7,973 System Rentals — — 12,643 — 12,643 Maintenance — 14,942 — — 14,942 Finance Income — — — 2,305 2,305 7,973 14,942 12,643 2,305 37,863 Sub-total for reportable segments 7,973 35,912 12,661 2,305 58,851 All Other 1,003 182 — — 1,185 Total $ 8,976 $ 36,094 $ 12,661 $ 2,305 $ 60,036

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Reporting Information by Reportable Segment	The following table presents the Company’s revenue and gross margin by reportable segment for the three months ended March 31, 2023 and 2022: Revenue (1) Gross Margin (In thousands of U.S. Dollars) 2023 2022 2023 2022 Content Solutions $ 32,101 $ 20,988 $ 17,995 $ 12,625 Technology Products and Services 51,667 37,863 29,891 18,416 Sub-total for reportable segments 83,768 58,851 47,886 31,041 All Other (2) 3,178 1,185 2,165 730 Total $ 86,946 $ 60,036 $ 50,051 $ 31,771 (1) The Company’s largest customer represents 9 % of total Revenues for the three months ended March 31, 2023 (2022 — 11 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of March 31, 2023 and December 31, 2022 . (2) All Other includes the results from IMAX Enhanced , SSIMWAVE, and other ancillary activities.
Summary of Revenues By Geographic Area	The following table summarizes the Company’s revenues by geographic area for the three months ended March 31, 2023 and 2022: Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 United States $ 26,753 $ 19,067 Greater China 26,566 21,476 Asia (excluding China) 10,652 5,767 Western Europe 10,168 7,061 Canada 7,196 1,772 Latin America 1,603 1,886 Russia/the CIS & Ukraine (1) 135 1,010 Rest of the World 3,873 1,997 Total $ 86,946 $ 60,036 (1) In addition to Russia, the Company has IMAX Systems in the Commonwealth of Independent States ( “CIS”) which are Azerbaijan, Belarus, Kazakhstan, and Kyrgyzstan. Commencing in March 2022, in response to the ongoing conflict between Russia and Ukraine and resulting sanctions, the Company suspended its operations in Russia and Belarus. As of March 31, 2023, the IMAX network includes 54 systems in Russia, eight systems in Ukraine, and one system in Belarus. United States and Greater China each comprises greater than 10% of the Company’s total revenues for the three months ended March 31, 2023 and 2022 .

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2023
Derivative Instruments Gain Loss [Line Items]
Fair Value of Financial Instruments	The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of March 31, 2023 As of December 31, 2022 (In thousands of U.S. Dollars) Carrying Estimated Carrying Estimated Level 1 Cash and cash equivalents (1) $ 99,246 $ 99,246 $ 97,401 $ 97,401 Equity securities (2) 1,050 1,050 1,035 1,035 Level 2 Net financed sales receivables (3) $ 100,425 $ 96,801 $ 101,052 $ 100,059 Net investment in sales-type leases (3) 30,762 30,716 28,332 27,972 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,428 3,428 3,398 3,398 Foreign exchange contracts — designated forwards (2) ( 176 ) ( 176 ) ( 649 ) ( 649 ) Wells Fargo Credit Facility borrowings (1) ( 20,000 ) ( 20,000 ) ( 25,000 ) ( 25,000 ) HSBC China Facility borrowings (1) ( 12,165 ) ( 12,165 ) ( 12,496 ) ( 12,496 ) Bank of China Facility borrowings (1) ( 379 ) ( 379 ) ( 374 ) ( 374 ) Federal Economic Development Loan (3) ( 2,043 ) ( 2,043 ) ( 1,782 ) ( 1,782 ) Convertible Notes (5) ( 230,000 ) ( 218,210 ) ( 230,000 ) ( 196,717 ) Level 3 Interest in film classified as a financial instrument (6) $ — $ — $ — $ — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. (3) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data. (6) Recorded at amortized cost less impairment losses. Inputs used in the calculation of estimated fair value include management’s projection of future box office and ancillary receipts for the film net of distribution costs and other costs in accordance with the investment agreement. See 15(e) below.
Fair Value of Foreign Exchange Contracts	The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Condensed Consolidated Financial Statements: Fair value of derivatives in foreign exchange contracts : March 31, December 31, (In thousands of U.S. Dollars) Balance Sheet Location 2023 2022 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 193 $ 50 Accrued and other liabilities ( 369 ) ( 699 ) $ ( 176 ) $ ( 649 )
Derivatives in Foreign Currency Hedging Relationships	The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Condensed Consolidated Financial Statements: Derivatives in foreign currency hedging relationships are as follows : Three Months Ended March 31, (In thousands of U.S. Dollars) 2023 2022 Foreign exchange contracts Derivative Gain — Forwards Recognized in OCI (Effective Portion) $ 134 $ 315 Location of Derivative Loss Reclassified from AOCI Three Months Ended March 31, (In thousands of U.S. Dollars) (Effective Portion) 2023 2022 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ ( 339 ) $ ( 29 )

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	3 Months Ended
	Mar. 31, 2023
Temporary Equity Disclosure [Abstract]
Summary of Movement of the Non-controlling Interest in Temporary Equity Related to Original Film Fund	The following table summarizes the movement of the non-controlling interest in temporary equity related to the Original Film Fund for the three months ended March 31, 2023 and 2022: March 31, (In thousands of U.S. Dollars) 2023 2022 Beginning balance $ 722 $ 758 Net income 9 3 Ending balance $ 731 $ 761

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details)	3 Months Ended
	Mar. 31, 2023
Variable Interest Entity [Line Items]
Number of variable interest entities	ten
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Number of variable interest entities primary beneficiary	five
Variable Interest Entity, Not Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Number of variable interest entities not a primary beneficiary	five

Basis of Presentation - VIEs To

Basis of Presentation - VIEs Total Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 821,521	$ 821,154
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	487,682	491,386
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	1,537	1,523
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	$ 248	$ 248

Recently Issued Accounting St_2

Recently Issued Accounting Standards - Additional Information (Details)	Mar. 31, 2023
ASU 2022-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2023
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
ASU 2022-04
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2023
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true

Acquisition - Schedule of Subje

Acquisition - Schedule of Subject to Revision Upon Completion of Valuation Procedures (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill	$ 52,815	$ 52,815

Receivables - Summary of Allowa

Receivables - Summary of Allowance For Credit Losses Related to Accounts Receivable (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 14,119	$ 11,946
Current period (reversal) provision, net	(241)	2,257
Write-offs	(115)
Foreign exchange	65	(19)
Ending balance	13,828	14,184
Theatre Operators [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	11,144	8,867
Current period (reversal) provision, net	(265)	1,981
Write-offs	(115)
Foreign exchange	60	(17)
Ending balance	10,824	10,831
Studios [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	1,699	1,994
Current period (reversal) provision, net	3	3
Foreign exchange	5	2
Ending balance	1,707	1,995
Other [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	1,276	1,085
Current period (reversal) provision, net	21	273
Ending balance	$ 1,297	$ 1,358

Receivables - Additional Inform

Receivables - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Sep. 07, 2022
Current Expected Credit Losses [Line Items]
Unsecured claims related to receivable from bankruptcy entities			$ 11,400,000
Finance Income related to the net investment in leases in nonaccrual status	$ 0	$ 0
Finance Income related to the financed sales receivables in nonaccrual status	100,000	200,000
Finance income related to financed sale receivables with billed amounts past due	800,000	700,000
Maximum [Member]
Current Expected Credit Losses [Line Items]
Finance income related to net investment in leases with billed amounts past due	100,000	100,000
Theatre Operators [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) in allowance for current expected credit losses, variable consideration receivables	(100,000)
Theatre Operators [Member] | Variable Consideration Receivables [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) investment in leases and financed sale receivables provision for current expected credit losses		5,600,000
Theatre Operators [Member] | Maximum [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) in allowance for current expected credit losses, variable consideration receivables		(600,000)
Theatre And Foreign Movie Studio [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) in allowance for current expected credit losses, accounts receivables	$ (400,000)	$ 2,200,000

Receivables - Schedule of Finan

Receivables - Schedule of Financing Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Net investment in leases
Gross minimum payments due under sales-type leases	$ 32,097	$ 29,727
Unearned finance income	(557)	(619)
Present value of minimum payments due under sales-type leases	31,540	29,108
Allowance for credit losses	(778)	(776)
Net investment in leases	30,762	28,332
Financed sales receivables
Gross minimum payments due under financed sales	141,119	141,337
Unearned finance income	(29,161)	(29,340)
Present value of minimum payments due under financed sales	111,958	111,997
Allowance for credit losses	(11,533)	(10,945)
Net financed sales receivables	100,425	101,052
Total financing receivables	131,187	129,384
Net financed sales receivables due within one year	33,721	32,366
Net financed sales receivables due after one year	66,704	68,686
Net financed sales receivables	$ 100,425	$ 101,052

Receivables - Schedule of Weigh

Receivables - Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Weighted-average remaining lease term (in years)
Sales-type lease arrangements	8 years 10 months 24 days	9 years
Weighted-average interest rate
Sales-type lease arrangements	8.25%	8.23%
Financed sales receivables	8.85%	8.79%

Receivables - Schedule of Net I

Receivables - Schedule of Net Investment In Leases by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	$ 2,200	$ 4,148
Net investment leases, By Origination Year, Before latest fiscal year	4,141	10,058
Net investment leases, By Origination Year, Two years before latest fiscal year	10,129	3,656
Net investment leases, By Origination Year, Three years before latest fiscal year	3,723	7,378
Net investment leases, By Origination Year, Four years before latest fiscal year	7,443	2,451
Net investment leases, By Origination Year, Prior	3,904	1,417
Net Investment in Lease, Total	31,540	29,108
In Good Standing [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	2,200	4,148
Net investment leases, By Origination Year, Before latest fiscal year	4,141	6,969
Net investment leases, By Origination Year, Two years before latest fiscal year	7,017	2,494
Net investment leases, By Origination Year, Three years before latest fiscal year	2,544	1,977
Net investment leases, By Origination Year, Four years before latest fiscal year	2,020
Net investment leases, By Origination Year, Prior	1,020	1,016
Net Investment in Lease, Total	18,942	16,604
Pre-Approved Transactions [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Before latest fiscal year		3,089
Net investment leases, By Origination Year, Two years before latest fiscal year	3,112	1,162
Net investment leases, By Origination Year, Three years before latest fiscal year	1,179	5,401
Net investment leases, By Origination Year, Four years before latest fiscal year	5,423	2,451
Net investment leases, By Origination Year, Prior	2,483
Net Investment in Lease, Total	12,197	12,103
Transactions Suspended [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Prior	401	401
Net Investment in Lease, Total	$ 401	$ 401

Receivables - Schedule of Fin_2

Receivables - Schedule of Financed Sale Receivables by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	$ 2,163	$ 10,524
Financed sales receivables, By Origination Year, Before lastest fiscal year	10,103	11,625
Financed sales receivables, By Origination Year, Two year before latest fiscal year	11,789	7,821
Financed sales receivables, By Origination Year, Three year before latest fiscal year	7,685	10,944
Financed sales receivables, By Origination Year, Four year before latest fiscal year	10,995	12,500
Financed sales receivables, By Origination Year, Prior	69,223	58,583
Financed sales receivables, Total	143,498	141,105
Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	111,958	111,997
In Good Standing [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	2,163	10,252
Financed sales receivables, By Origination Year, Before lastest fiscal year	9,830	8,643
Financed sales receivables, By Origination Year, Two year before latest fiscal year	8,617	6,280
Financed sales receivables, By Origination Year, Three year before latest fiscal year	6,381	8,541
Financed sales receivables, By Origination Year, Four year before latest fiscal year	8,149	9,854
Financed sales receivables, By Origination Year, Prior	45,647	39,912
In Good Standing [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	80,787	83,482
Credit Watch [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Before lastest fiscal year	1
Financed sales receivables, By Origination Year, Prior	943	1,152
Credit Watch [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	944	1,152
Pre-Approved Transactions [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Before lastest fiscal year		2,318
Financed sales receivables, By Origination Year, Two year before latest fiscal year	2,377	1,399
Financed sales receivables, By Origination Year, Three year before latest fiscal year	1,162	1,134
Financed sales receivables, By Origination Year, Four year before latest fiscal year	1,590	1,449
Financed sales receivables, By Origination Year, Prior	13,220	9,243
Pre-Approved Transactions [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	18,349	15,543
Transactions Suspended [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year		272
Financed sales receivables, By Origination Year, Before lastest fiscal year	272	664
Financed sales receivables, By Origination Year, Two year before latest fiscal year	795	142
Financed sales receivables, By Origination Year, Three year before latest fiscal year	142	1,269
Financed sales receivables, By Origination Year, Four year before latest fiscal year	1,256	1,197
Financed sales receivables, By Origination Year, Prior	9,413	8,276
Transactions Suspended [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	$ 11,878	$ 11,820

Receivables - Schedule of Aging

Receivables - Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 21,233	$ 19,415
Unbilled	122,265	121,690
Financed sales receivables, Total	143,498	141,105
Allowance for Credit Losses	(12,311)	(11,721)
Total financing receivables	131,187	129,384
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	3,560	3,046
Unbilled	27,980	26,062
Financed sales receivables, Total	31,540	29,108
Allowance for Credit Losses	(778)	(776)	$ (706)	$ (798)
Total financing receivables	30,762	28,332
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	17,673	16,369
Unbilled	94,285	95,628
Financed sales receivables, Total	111,958	111,997
Allowance for Credit Losses	(11,533)	(10,945)	$ (11,135)	$ (5,414)
Total financing receivables	100,425	101,052
Accrued and Current [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,587	2,506
Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	235	237
Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,352	2,269
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	3,623	1,523
30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	433	216
30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	3,190	1,307
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	16,023	15,386
Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	2,892	2,593
Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 13,131	$ 12,793

Receivables - Schedule of Net_2

Receivables - Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 21,233	$ 19,415
Unbilled	122,265	121,690
Allowance for Credit Losses	(12,311)	(11,721)
Total financing receivables	131,187	129,384
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	3,560	3,046
Unbilled	27,980	26,062
Allowance for Credit Losses	(778)	(776)	$ (706)	$ (798)
Total financing receivables	30,762	28,332
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	17,673	16,369
Unbilled	94,285	95,628
Allowance for Credit Losses	(11,533)	(10,945)	$ (11,135)	$ (5,414)
Total financing receivables	100,425	101,052
Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,587	2,506
Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	235	237
Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,352	2,269
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	3,623	1,523
30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	433	216
30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	3,190	1,307
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	16,023	15,386
Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,892	2,593
Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	13,131	12,793
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	17,240	16,443
Unbilled	61,071	60,242
Allowance for Credit Losses	(1,688)	(1,817)
Total financing receivables	76,623	74,868
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	3,499	2,964
Unbilled	18,286	17,070
Allowance for Credit Losses	(228)	(230)
Total financing receivables	21,557	19,804
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	13,741	13,479
Unbilled	42,785	43,172
Allowance for Credit Losses	(1,460)	(1,587)
Total financing receivables	55,066	55,064
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,160	1,740
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	220	190
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	940	1,550
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,743	1,296
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	387	181
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,356	1,115
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	13,337	13,407
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,892	2,593
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 10,445	$ 10,814

Receivables - Schedule of Net_3

Receivables - Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	$ 20,862	$ 27,765
Allowance for Credit Losses	(8,000)	(9,990)
Net	12,862	17,775
Net Investment in Leases [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	401	401
Allowance for Credit Losses	(401)	(401)
Net Financed Sales Receivables [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	20,461	27,364
Allowance for Credit Losses	(7,599)	(9,589)
Net	$ 12,862	$ 17,775

Receivables - Summary of Allo_2

Receivables - Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	$ 11,721
Ending balance	12,311
Net Investment in Leases [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	776	$ 798
Current period (reversal) provision, net	(2)	(93)
Foreign exchange	4	1
Ending balance	778	706
Net Financed Sales Receivables [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	10,945	5,414
Current period (reversal) provision, net	549	5,708
Foreign exchange	39	13
Ending balance	$ 11,533	$ 11,135

Receivables - Summary of Allo_3

Receivables - Summary of Allowance For Credit Losses Related to Variable Consideration Receivables (Details) - Theatre Operators [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 610	$ 1,082
Current period provision (reversal), net	(86)	(643)
Foreign exchange	2
Ending balance	$ 526	$ 439

Lease Arrangements - Additional

Lease Arrangements - Additional Information (Details)	3 Months Ended
	Mar. 31, 2023 Lease
Leases [Line Items]
Lessee, operating lease description	The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term.
Lessee, operating lease, existence of option to extend term	true
Lessee, operating lease, existence of option to extend description	The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs and its level of investment in leasehold improvements, among other factors.
Lessee, operating lease, assumptions for discount rate	The incremental borrowing rate used in the calculation of the Company’s lease liabilities is based on the location of each leased property.
Leases include options to purchase leased property	0
Lessee, operating lease, existence of residual value	false
Lessee, operating lease, sublease options	The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed.
Lessor, sales-type lease description	The Company provides IMAX Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system.
Minimum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	1 year
Sales-type lease, lease term	10 years
Non-cancellable term of joint revenue sharing arrangements	10 years
Maximum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	5 years
Non-cancellable term of joint revenue sharing arrangements	or longer

Lease Arrangements - Components

Lease Arrangements - Components of Operating Lease Expense (Details) - Selling, General and Administrative Expenses [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Line Items]
Amortization of operating lease assets	$ 151	$ 693
Interest on operating lease liabilities	724	215
Short-term and variable lease costs	204	160
Amortization of finance lease assets	100
Interest on finance lease liabilities	14
Total lease cost	$ 1,193	$ 1,068

Lease Arrangements - Supplement

Lease Arrangements - Supplemental Cash and Non-Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Operating leases	$ 971	$ 945
Supplemental Disclosure of Noncash Leasing Activities [Abstract]
Right-of-use assets obtained in exchange for operating lease obligations	$ 228	$ 217

Lease Arrangements - Lessee Ope

Lease Arrangements - Lessee Operating Lease Balance Sheet Amounts and Lines (Details) - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Leases [Line Items]
Operating lease right-of-use assets		$ 11,888	$ 12,341
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]		Property, Plant and Equipment, Net	Property, Plant and Equipment, Net
Finance lease right-of-use assets		$ 1,776	$ 1,876
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]		Property, Plant and Equipment, Net
Operating lease liabilities		$ 14,140	$ 14,461
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Accrued Liabilities and Other Liabilities	Accrued Liabilities and Other Liabilities
Finance lease liabilities	[1]	$ 967	$ 1,011
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Accrued Liabilities and Other Liabilities
[1] Recorded net of a $ 0.9 million upfront payment made upon execution of the finance lease arrangement.

Lease Arrangements - Lessee O_2

Lease Arrangements - Lessee Operating Lease Balance Sheet Amounts and Lines (Parenthetical) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Leases [Abstract]
Upfront payment made upon execution of finance lease	$ 0.9

Lease Arrangements - Lessee Lea

Lease Arrangements - Lessee Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate (Details)	Mar. 31, 2023	Dec. 31, 2022
Operating Leases [Abstract]
Weighted-average remaining lease term (years)	5 years 9 months 18 days	6 years
Weighted-average discount rate	5.91%	5.90%
Finance Leases [Abstract]
Weighted-average remaining lease term (years)	4 years 4 months 24 days	4 years 8 months 12 days
Weighted-average discount rate	6%	6%

Lease Arrangements - Lessee O_3

Lease Arrangements - Lessee Operating and Finance Lease, Maturity (Details) - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Lessee, Operating Lease, Liability, to be Paid [Abstract]
2023 (nine months remaining)		$ 2,699
2024		3,049
2025		2,457
2026		2,069
2027		2,093
Thereafter		4,354
Total lease payments		16,721
Less: interest expense		(2,581)
Present value of operating lease liabilities		$ 14,140	$ 14,461
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Accrued and other liabilities	Accrued and other liabilities
Finance Lease, Liability, to be Paid [Abstract]
2023 (nine months remaining)		$ 508
2024		508
Total lease payments		1,016
Less: interest expense		(49)
Present value of finance lease liabilities	[1]	$ 967	$ 1,011
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]		Accrued Liabilities and Other Liabilities
[1] Recorded net of a $ 0.9 million upfront payment made upon execution of the finance lease arrangement.

Lease Arrangements - Schedule o

Lease Arrangements - Schedule of Maturities of Lease Receivables (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Sales-type leases
2023 (nine months remaining)	$ 2,260
2024	3,519
2025	3,248
2026	3,163
2027	3,018
Thereafter	16,889
Total	32,097
Joint Revenue Sharing Arrangements
2023 (nine months remaining)	130
2024	69
2025	27
Total	$ 226

Inventories - Inventories (Deta

Inventories - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventories
Raw materials	$ 29,554	$ 25,365
Work-in-process	2,220	2,034
Finished goods	5,718	4,135
Total	$ 37,492	$ 31,534

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Inventory [Line Items]
Finished goods inventory with title passed to customer	$ 5,300		$ 3,500
Write-downs for excess and damaged inventory	6	$ 12
Technology Sales [Member] | Maximum [Member]
Inventory [Line Items]
Write-downs for excess and damaged inventory	$ 100	$ 100

Borrowings - Revolving Credit F

Borrowings - Revolving Credit Facility Borrowings, Net (Details) ¥ in Millions	Mar. 31, 2023 USD ($)	Mar. 31, 2023 CNY (¥)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CNY (¥)	Mar. 31, 2022 USD ($)
Wells Fargo Credit Facility [Member]
Bank indebtedness [Line Items]
Borrowings	$ 20,000,000		$ 25,000,000		$ 0
Revolving Credit Facility [Member]
Bank indebtedness [Line Items]
Unamortized debt issuance costs	(1,519,000)		(1,759,000)
Revolving Credit Facility Borrowings, net	31,025,000		36,111,000
Bank of China Facility [Member]
Bank indebtedness [Line Items]
Borrowings	400,000	¥ 2.6	400,000	¥ 2.6
Bank of China Facility [Member] | Revolving Credit Facility [Member]
Bank indebtedness [Line Items]
Borrowings	379,000		374,000
HSBC China Facility [Member]
Bank indebtedness [Line Items]
Borrowings	$ 12,200,000	¥ 83.6	$ 12,500,000	¥ 87

Borrowings - Additional Informa

Borrowings - Additional Information (Details) ¥ in Millions

3 Months Ended

12 Months Ended

48 Months Ended

Mar. 25, 2022 USD ($)

Mar. 19, 2021 USD ($)

May 29, 2019 USD ($)

Mar. 31, 2023 USD ($) $ / shares

Mar. 31, 2022 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2022 USD ($)

Mar. 31, 2023 CNY (¥)

Dec. 31, 2022 CNY (¥)

Jun. 30, 2022 USD ($)

Jun. 30, 2022 CNY (¥)

Oct. 31, 2019 USD ($)

May 29, 2019 CAD ($)

Borrowings (Textual) [Abstract]

Credit facility description

On March 25, 2022, the Company entered into a Sixth Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as agent (the “Agent”), and a syndicate of lenders party thereto (the “Credit Agreement”), which extended the maturity date of the credit facility under the Credit Agreement (the “Credit Facility”) from June 28, 2023 to March 25, 2027. The Company’s obligations under the Credit Agreement are guaranteed by certain of the Company’s subsidiaries (the “Guarantors”), and are secured by first-priority security interests in substantially all of the assets of the Company and the Guarantors.

Credit facility maturity date

Mar. 25, 2027

Current borrowing capacity

$ 300,000,000

Line of credit facility covenant terms

The Credit Facility requires that the Company maintain a maximum Senior Secured Net Leverage Ratio (as defined in the Credit Agreement) of no greater than 3.25:1.00, on the last day of each Fiscal Quarter.

Letters of guarantee outstanding

$ 400,000

$ 400,000

$ 400,000

¥ 3

¥ 2.8

Debt issuance costs paid

$ 1,783,000

Convertible Notes [Member]

Borrowings (Textual) [Abstract]

Borrowings

230,000,000

230,000,000

230,000,000

Debt instrument, principal amount

$ 230,000,000

$ 230,000,000

Debt instrument, annual interest rate

0.50%

0.50%

0.50%

Proceeds from issuance of convertible notes, net

$ 223,700,000

Debt instrument, frequency of periodic interest payment

semi-annually

Debt instrument, payment terms

The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500% per annum on the principal of $230.0 million, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021.

Debt instrument, date of first required payment

Oct. 01, 2021

Debt instrument, maturity date

Apr. 01, 2026

Debt instrument, convertible, terms of conversion feature

Holders of the Convertible Notes have the right to convert their Convertible Notes in certain circumstances and during specified periods. Before January 1, 2026, holders of the Convertible Notes have the right to convert their Convertible Notes only upon the occurrence of certain events. From and after January 1, 2026, holders of the Convertible Notes may convert their Convertible Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as applicable, cash or a combination of cash (in an amount no less than the principal amount of the Convertible Notes being converted) and common shares, at its election, based on the applicable conversion rates. The initial conversion rate is 34.7766 common shares per $1,000 principal amount of Convertible Notes, which represents an initial conversion price of approximately $28.75 per common share, and is subject to adjustment upon the occurrence of certain events.

Debt instrument, initial conversion rate per $1,000 principal amount

34.7766

Convertible notes principal amount

$ 1,000

Debt instrument, initial conversion price | $ / shares

$ 28.75

Debt instrument, redemption, description

The Convertible Notes are redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after April 6, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price for a specified period of time. In addition, calling any Convertible Notes for redemption will constitute a “make-whole fundamental change” with respect to such notes, in which case the conversion rate applicable to the conversion of such notes will be increased in certain circumstances if such notes are converted after they are called for redemption.

Debt instrument, redemption start date

Apr. 06, 2024

Convertible Notes [Member] | Call Option [Member]

Borrowings (Textual) [Abstract]

Cap price of capped call transactions | $ / shares

37.2750

Percentage of premium of cap price over last reported sale price per common share on March 16, 2021

75%

Cost of capped call transactions

$ 19,100,000

Reduction to other equity

$ 19,100,000

Bank of China Facility [Member]

Borrowings (Textual) [Abstract]

Credit facility description

In June 2022, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company’s majority-owned subsidiaries in China, renewed its unsecured revolving facility with Bank of China for up to 200.0 million Chinese Renminbi (“RMB”) ($29.1 million), including RMB 10.0 million ($1.4 million) for letters of guarantee, to fund ongoing working capital requirements (the “Bank of China Facility”).

Current borrowing capacity

$ 29,100,000

¥ 200

Borrowings

$ 400,000

$ 400,000

400,000

¥ 2.6

2.6

Effective interest rate

3.85%

4.15%

Line of credit facility expiration period

2023-09

Letters of guarantees borrowing capacity

1,400,000

10

Remaining borrowing capacity

$ 27,300,000

187.4

HSBC China Facility [Member]

Borrowings (Textual) [Abstract]

Current borrowing capacity

$ 29,100,000

¥ 200

Borrowings

$ 12,200,000

$ 12,500,000

12,500,000

83.6

¥ 87

Effective interest rate

3.88%

3.91%

Remaining borrowing capacity

$ 16,900,000

116.4

Federal Economic Development Loan Payable [Member]

Borrowings (Textual) [Abstract]

Loans payable

3,128,000

$ 2,812,000

2,812,000

Debt instrument, fair value

2,043,000

1,782,000

$ 1,782,000

Federal Economic Development Loan Payable [Member] | Interest Income [Member]

Borrowings (Textual) [Abstract]

Interest free benefit of government funding

100,000

Federal Economic Development Loan Payable [Member] | Interest Expense [Member]

Borrowings (Textual) [Abstract]

Interest accretion expense

100,000

Federal Economic Development Loan Payable [Member] | SSIMWAVE Inc. [Member]

Borrowings (Textual) [Abstract]

Debt instrument, annual interest rate

0%

0%

Percentage of contributions cover eligible and supported costs

35%

Contributions repayable months

60 months

Debt instrument repayment beginning month and year

2024-01

Foreign Exchange Facility [Member]

Borrowings (Textual) [Abstract]

Unrealized gain (loss) on outstanding foreign currency forward contracts

(200,000)

(600,000)

$ (600,000)

Notional Amount of arrangements entered into

34,400,000

24,700,000

24,700,000

Letter of Credit | Bank of China Facility [Member]

Borrowings (Textual) [Abstract]

Remaining borrowing capacity

$ 1,000,000

¥ 7

NBC Facility [Member]

Borrowings (Textual) [Abstract]

Credit facility maturity date

Jun. 30, 2023

Current borrowing capacity

$ 5,000,000

Remaining borrowing capacity

$ 0

0

0

Wells Fargo Credit Facility [Member]

Borrowings (Textual) [Abstract]

Borrowings

20,000,000

0

25,000,000

25,000,000

Letters of credit or advance payment guarantees

$ 0

$ 0

$ 0

Line of credit facility covenant terms

The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit indebtedness, liens, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets. The Credit Agreement also contains customary representations, warranties and event of default provisions.The Company incurred fees of approximately $2.5 million in connection with the March 25, 2022 amendment of the Credit Agreement, which are being amortized on a straight-line basis over the term of the Credit Agreement. In the first quarter of 2022, the Company expensed $0.4 million in unamortized deferred financing costs associated with lenders that are no longer parties to the Credit Agreement.

Debt instrument net leverage ratio

0

Interest rate description

Loans under the Credit Facility bear interest, at the Company’s option, at (i) Term Secure Overnight Financing Rate (“SOFR”), Eurocurrency Rate or Canadian Dollar Offered Rate (“CDOR”) plus a margin ranging from 1.00% to 1.75% per annum; or (ii) the U.S. base rate or the Canadian prime rate plus a margin ranging from 0.25% to 1.00% per annum, in each case depending on the Company’s total leverage ratio. In no event will Term SOFR, Eurocurrency Rate or CDOR Rate be less than 0.00% per annum.

Effective interest rate

6.35%

Fees incurred with amendments

$ 2,500,000

Unamortized deferred financing costs expenses

$ 400,000

Remaining borrowing capacity

$ 280,000,000

Wells Fargo Credit Facility [Member] | Secure Overnight Financing Rate, Eurocurrency Rate or Canadian Dollar Offered Rate [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

1.75%

Interest rate maximum margin percentage

0%

Minimum [Member]

Borrowings (Textual) [Abstract]

Borrowing capacity under uncommitted accordion feature

$ 140,000,000

Minimum [Member] | Convertible Notes [Member]

Borrowings (Textual) [Abstract]

Percentage of last reported sale price per common share against conversion price for specific period of time

130%

Minimum [Member] | Wells Fargo Credit Facility [Member] | Secure Overnight Financing Rate, Eurocurrency Rate or Canadian Dollar Offered Rate [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

1%

Minimum [Member] | Wells Fargo Credit Facility [Member] | U.S. Base Rate or Canadian Prime Rate [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

0.25%

Maximum [Member]

Borrowings (Textual) [Abstract]

Borrowing capacity under uncommitted accordion feature

$ 440,000,000

Maximum [Member] | Federal Economic Development Loan Payable [Member] | SSIMWAVE Inc. [Member]

Borrowings (Textual) [Abstract]

Debt instrument, principal amount

$ 3,100,000

$ 4,200,000

Maximum [Member] | Wells Fargo Credit Facility [Member]

Borrowings (Textual) [Abstract]

Debt instrument net leverage ratio

3.25

Unrestricted cash and cash equivalents held outside of People's Republic of China

$ 75,000,000

Maximum [Member] | Wells Fargo Credit Facility [Member] | Secure Overnight Financing Rate, Eurocurrency Rate or Canadian Dollar Offered Rate [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

1.75%

Maximum [Member] | Wells Fargo Credit Facility [Member] | U.S. Base Rate or Canadian Prime Rate [Member]

Borrowings (Textual) [Abstract]

Interest rate margin percentage

1%

Borrowings - Summary of Convert

Borrowings - Summary of Convertible Notes, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Bank indebtedness [Line Items]
Revolving Credit Facility Borrowings, net	$ 227,549	$ 226,912
Convertible Notes and Other Borrowings, net	227,549	226,912
Convertible Notes [Member]
Bank indebtedness [Line Items]
Borrowings	230,000	230,000
Unamortized discounts and debt issuance costs	(4,494)	(4,870)
Revolving Credit Facility Borrowings, net	225,506	225,130
Federal Economic Development Loan [Member]
Bank indebtedness [Line Items]
Loans payable	3,128	2,812
Unaccreted interest benefit	(1,085)	(1,030)
Debt instrument, fair value, Total	$ 2,043	$ 1,782

Commitments, Contingencies an_2

Commitments, Contingencies and Guarantees - Additional Information (Details) - USD ($)	3 Months Ended	51 Months Ended	95 Months Ended
	Mar. 31, 2023	Mar. 27, 2008	Dec. 02, 2011	Dec. 31, 2022
Loss Contingencies [Line Items]
Final Award in favor of company		amount of $11.3 million, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid	$30,000 to cover the costs of the application
Final Award amount issued		$ 11,300,000
Final Award additional interest		$ 2,512
Final Award settlement cost			$ 30,000
Award inclusive of interest	$ 25,500,000
Product warranty accrual	100,000			$ 0
Indemnification of its directors/officers	0			$ 0
Other Indemnification	$ 0

Condensed Consolidated Statem_9

Condensed Consolidated Statements of Operations Supplemental Information - Summary of Selling Expenses, Including Sales Commissions and Other Selling Expenses (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Collaborative Arrangements [Line Items]
Sales Commissions		$ 273	$ 45
Marketing and Other		7,048	3,542
Technology Sales [Member]
Collaborative Arrangements [Line Items]
Sales Commissions	[1]	200
Marketing and Other	[1]	16	162
Image Enhancement and Maintenance Services [Member]
Collaborative Arrangements [Line Items]
Marketing and Other	[2]	6,772	2,915
Technology Rentals [Member]
Collaborative Arrangements [Line Items]
Sales Commissions	[3]	73	45
Marketing and Other	[3]	$ 260	$ 465
[1] Sales commissions paid prior to the recognition of the related revenue are deferred and recognized upon the client acceptance of the IMAX System. Direct advertising and marketing costs for each IMAX System are expensed as incurred. Film exploitation costs, including advertising and marketing costs, are expensed as incurred. Sales commissions related to joint revenue sharing arrangements accounted for operating leases are recognized in the month they are earned by the salesperson, which is typically the month in which the IMAX System is installed. Direct advertising and marketing costs for each IMAX System are expensed as incurred.

Condensed Consolidated State_10

Condensed Consolidated Statements of Operations Supplemental Information - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) Film	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Foreign Exchange
Foreign exchange translation gain (loss)	$ (100)	$ (100)
Collaborative Arrangements
Average percentage of the box-office receipts of the film for recovering digital re-mastering cost	12.50%
Revenue attributable to transactions arising between the company and its customers under IMAX film remastering and distribution arrangements	$ 30,100	19,600
Number of significant co-produced film arrangement | Film	1
Number of other co-produced film arrangements | Film	4
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 821,521		$ 821,154
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	487,682		491,386
Amounts attributable to transactions between the company and other parties involved in the production of films included in costs and expenses	100	100
Variable Interest Entity, Primary Beneficiary [Member]
Collaborative Arrangements
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	1,537		1,523
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	248		$ 248
Retrospective adoption of ASC Topic 606, Revenue from Contracts with Customers [Member]
Collaborative Arrangements
Revenue attributable to transactions arising between the company and its customers under joint revenue sharing arrangements	$ 20,100	$ 13,600

Condensed Consolidated State_11

Condensed Consolidated Statements of Cash Flows Supplemental Information - Summary of Changes in Other Operating Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
(Increase) Decrease in:
Financing receivables	$ (1,625)	$ 3,916
Prepaid expenses	(2,406)	(2,413)
Variable consideration receivables	(3,440)	829
Other assets	80	209
Increase (decrease) in:
Accounts payable	513	2,184
Accrued and other liabilities	(1,466)	(14,911)
Changes in other operating assets and liabilities	$ (8,344)	$ (10,186)

Condensed Consolidated State_12

Condensed Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Summary of Depreciation and amortization
Film assets		$ 3,452	$ 3,178
Property, plant and equipment:
Equipment supporting joint revenue sharing arrangements		5,772	5,548
Other property, plant and equipment	[1]	2,287	2,028
Other intangible assets	[2]	1,399	1,532
Other assets	[3]	410	455
Depreciation and amortization		$ 13,320	$ 12,741
[1] Includes the amortization of laser projection systems, camera, and lens upgrades recorded in Research and Development on the Condensed Consolidated Statement of Operations of $ 0.1 million in the three months ended March 31, 2023 (2022 — $ 0.2 million ). Includes the amortization of licenses and intellectual property recorded in Research and Development on the Condensed Consolidated Statement of Operations of $ 0.3 million in the three months ended March 31, 2023 (2022 — $ 0.3 million ). Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements.

Condensed Consolidated State_13

Condensed Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization (Parenthetical) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Amortization of property, plant and equipment net in research and development	$ 0.1	$ 0.2
Amortization of intangible assets net in research and development	$ 0.3	$ 0.3

Condensed Consolidated State_14

Condensed Consolidated Statements of Cash Flows Supplemental Information - Write Downs, Net of Recoveries (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Write-downs
Equipment supporting joint revenue sharing arrangements	[1]	$ 297	$ 202
Other property, plant and equipment		1	2
Inventories		6	12
Film assets			165
Write-downs		$ 304	$ 381
[1] In the three months ended March 31, 2023, the Company recorded charges of $ 0.3 million (2022 — $ 0.2 million ) in Costs and Expenses Applicable to Revenues ― Technology Rentals mostly related to the write-down of leased xenon-based digital systems which were taken out of service in connection with customer upgrades to laser-based digital systems, as well as the closure of one IMAX System.

Condensed Consolidated State_15

Condensed Consolidated Statements of Cash Flows Supplemental Information - Write-downs (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Supplemental Cash Flow Elements [Line Items]
Theater system components written off in Costs and expenses	$ 300	$ 200
Write-downs for excess inventory	6	12
Maximum [Member] | Technology Sales [Member]
Supplemental Cash Flow Elements [Line Items]
Write-downs for excess inventory	$ 100	$ 100

Condensed Consolidated State_16

Condensed Consolidated Statements of Cash Flows Supplemental Information - Significant Non-cash Investing Activities - (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net (decrease) increase in accruals related to:
Investment in equipment supporting joint revenue sharing arrangements	$ (764)	$ 1,133
Acquisition of other intangible assets	(22)	32
Purchases of property, plant and equipment	548
Net accruals	$ (238)	$ 1,165

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Income Tax Contingency [Line Items]
Income tax expense (benefit)	$ 4,885	$ 2,610
Deferred tax asset, valuation allowance	64,500		$ 62,900
Additional deferred tax asset, valuation allowance	1,600	$ 5,000
Deferred tax liabilities	16,000		14,900
Deferred income tax asset after valuation allowance	$ 11,200		$ 9,900

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Tax Rates (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax (expense) benefit at combined statutory rates, Amount	$ (2,652)	$ 2,475
Increase in valuation allowance, Amount	(1,610)	(5,009)
Shortfall tax benefits related to share-based compensation, Amount	(83)	(129)
Changes to tax reserves, Amount	(258)	(160)
Other, Amount	(282)	213
Income tax expense	$ (4,885)	$ (2,610)
Income tax (expense) benefit at combined statutory rates, Rate	26.50%	26.50%
Change of valuation allowance, Rate	16.10%	(53.60%)
Shortfall tax benefits related to share-based compensation. Rate	0.80%	(1.40%)
Changes to tax reserves, Rate	2.60%	(1.70%)
Other	2.80%	2.30%
Income tax expense	48.80%	(27.90%)

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense in Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Unrealized change in cash flow hedging instruments	$ (35)	$ (82)
Realized change in cash flow hedging instruments	(89)	(8)
Defined benefit and postretirement benefit plans	46	(12)
Income tax benefit related to other comprehensive (loss) income	$ (78)	$ (102)

Capital Stock and Reserves - Ad

Capital Stock and Reserves - Additional Information (Details) $ / shares in Units, $ / shares in Units, ¥ in Millions, $ in Millions	1 Months Ended	3 Months Ended			12 Months Ended
	Jan. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2022 HKD ($) $ / shares shares	Dec. 31, 2022 shares	Mar. 31, 2023 CNY (¥) shares	Jun. 23, 2022 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation costs recorded for the period | $		$ 6,100,000	$ 5,100,000
Stock-based compensation expense | $		$ 5,059,000	$ 6,052,000
Maximum number of shares of common stock may be issued for outstanding PSU		54,589,933			54,148,614	54,589,933
Common shares purchased in open market by trustee in connection with RSUs		0	0	0
Number of treasury shares held in trust for future settlement of share based awards		0			0
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units		4,260,382	6,348,736	6,348,736
Percentage of statutory net profits to statutory surplus reserve to be appropriated		10%				10%
Discontinuation of contribution, Aggregate sum of statutory surplus reserve more than its registered capital,percent.		50%				50%
Statutory surplus reserve appropriated		$ 5,600,000				¥ 36.4
Statutory surplus reserve to its subsidiaries registered capital percent		50%				50%
IMAX China
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program		In 2022, IMAX China Holding, Inc. (“IMAX China”)’s shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase shares of IMAX China not to exceed 10% of the total number of issued shares as of June 23, 2022 (34,063,480 shares). This program will be valid until the 2023 Annual General Meeting of IMAX China on June 6, 2023. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time.
Stock Repurchase Program Expiration Date		Jun. 23, 2022
Repurchase of common shares		0	1,448,000	1,448,000
Stock Acquired, Average Cost per Share | (per share)			$ 1.26	$ 9.89
Change in ownership interest related to IMAX China common share repurchases			$ 1,800,000	$ 14.3
Stock Repurchase Program, maximum percentage of shares to be repurchased							10%
Stock Repurchase Program, Authorized number of shares							34,063,480
Parent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program		In 2022, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2023 and an increase of $200.0 million in the share repurchase program. With the increase of $200.0 million, the Company’s total share repurchase authority is $400.0 million under the current share repurchase program. As of March 31, 2023, the Company has $191.8 million available under its approved repurchased program. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.
Stock Repurchase Program, Authorized Amount | $		$ 191,800,000
Stock Repurchase Program Expiration Date		Jun. 30, 2023
Repurchase of common shares	140,000	109,477	380,652	380,652
Stock Acquired, Average Cost per Share | $ / shares	$ 14.45	$ 14.87	$ 16.45
Change in ownership interest related to IMAX China common share repurchases | $	$ 2,000,000	$ 1,600,000	$ 6,300,000
Stock Repurchase Program, Authorized number of shares					200,000,000
Parent [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Repurchase Program, Authorized Amount | $		400,000,000
Non-controlling Interests [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Change in ownership interest related to IMAX China common share repurchases | $			1,301,000
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense | $		$ 3,365,000	$ 3,411,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units		620,553	1,444,455	1,444,455
Restricted Share Units [Member] | Non Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense | $		$ 0	$ 0
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense | $		$ 84,000	$ 207,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units		3,460,373	3,607,391	3,607,391
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense | $		$ 924,000	$ 1,729,000
Stock based awards vesting period		3 years
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		175%
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units		179,456	1,296,890	1,296,890
Performance Stock Units [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		0%
Performance Stock Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage		175%
Performance Stock Units [Member] | EBITDA | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of common stock may be issued for outstanding PSU		1,635,522				1,635,522

Capital Stock and Reserves - St

Capital Stock and Reserves - Stock Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 5,059	$ 6,052
Costs and Expenses Applicable to Revenues [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	263	239
Selling, General and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	5,196	5,726
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	99	$ 87
Executive Transition Costs [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ (499)

Capital Stock and Reserves - _2

Capital Stock and Reserves - Stock-based Compensation by Plan Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	$ 5,059	$ 6,052
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	84	207
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	3,365	3,411
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	924	1,729
IMAX China Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	10	34
IMAX China Long Term Incentive Plan Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	541	497
IMAX China Long Term Incentive Plan Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	$ 135	$ 174

Capital Stock and Reserves - Sc

Capital Stock and Reserves - Schedule of Share-based Compensation, Stock Options, Activity (Details) - Employee Stock Option [Member] - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding, beginning of period	3,604,739	3,736,157
Expired	(144,366)	(126,569)
Cancelled		(2,197)
Stock options outstanding, end of period	3,460,373	3,607,391
Stock options exercisable, end of period	3,460,373	3,524,298
Stock options outstanding, weighted average exercise price per share	$ 26.36	$ 26.61
Expired, weighted average exercise price per share	31.85	33.61
Cancelled, weighted average exercise price per share		32.50
Stock options outstanding, weighted average exercise price per share	26.13	26.36
Stock options exercisable, weighted average exercise price per share, end of period	$ 26.13	$ 26.45

Capital Stock and Reserves - Re

Capital Stock and Reserves - Restricted Stock Units Activity under the IMAX LTIP (Details) - Restricted Share Units [Member] - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards outstanding, beginning of period	1,252,044	1,457,883
Granted	811,529	636,427
Vested and settled	(677,611)	(648,527)
Forfeited	(19,509)	(1,328)
Number of awards outstanding,end of period	1,366,453	1,444,455
Weighted average grant date fair value per share, beginning of period	$ 19.16	$ 19.16
Granted, weighted average grant date fair value per share	17.73	19.64
Vested and settled, weighted average grant date fair value per share	18.70	18.78
Forfeited, weighted average grant date fair value per share	19.80	14.84
Weighted average grant date fair value per share, end of period	$ 18.53	$ 19.54

Capital Stock and Reserves - Pe

Capital Stock and Reserves - Performance Stock Units Activity under the IMAX LTIP (Details) - Performance Stock Units [Member] - $ / shares		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards outstanding, beginning of period		931,716	613,405
Granted	[1]	580,118	359,138
Forfeited		(208,648)
Vested and settled	[1]	(368,602)
Number of awards outstanding,end of period		934,584	972,543
Weighted average grant date fair value per share, beginning of period		$ 18.96	$ 18.21
Granted, weighted average grant date fair value per share	[1]	17.68	20.34
Forfeited, weighted average grant date fair value per share		18.09
Vested and settled, weighted average grant date fair value per share	[1]	16.92
Weighted average grant date fair value per share, end of period		$ 19.16	$ 19
[1] For the three months ended March 31, 2023 , the balance of shares granted includes 157,963 additional shares, at a weighted average grant date fair value per share of $ 16.92 , as PSUs granted in 2020 with EBITDA-based targets vested at 175 % on account of full achievement of the targets. This performance adjustment in the first quarter of 2023 reflects the Company's performance assessment of its first PSU awards.

Capital Stock and Reserves - _3

Capital Stock and Reserves - Performance Stock Units Activity under the IMAX LTIP (Parenthetical) (Details) - Performance Stock Units [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Additional shares granted | shares	157,963
Additional shares granted, weighted average grant date fair value per share | $ / shares	$ 16.92
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage	175%

Capital Stock and Reserves - Ba

Capital Stock and Reserves - Basic and Diluted Per-share Computations (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Equity [Abstract]
Issued and outstanding, beginning of period	54,149	58,654
Weighted average number of shares (repurchased) issued, net	(85)	(80)
Weighted average number of shares outstanding - basic	54,064	58,574
Weighted average effect of potential common shares, if dilutive	927
Weighted average number of shares outstanding - diluted	54,991	58,574

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue by Segment (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Revenues	[1]	$ 86,946	$ 60,036
Technology Sales [Member]
Disaggregation of Revenue [Line Items]
Revenues		17,822	8,976
Image Enhancement and Maintenance Services [Member]
Disaggregation of Revenue [Line Items]
Revenues		47,127	36,094
Technology Rentals [Member]
Disaggregation of Revenue [Line Items]
Revenues		20,058	12,661
Finance Income [Member]
Disaggregation of Revenue [Line Items]
Revenues		1,939	2,305
Content Solutions Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	32,101	20,988
Content Solutions Segment [Member] | Film Remastering And Distribution [Member]
Disaggregation of Revenue [Line Items]
Revenues		30,073	19,564
Content Solutions Segment [Member] | Other Content Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenues		2,028	1,424
Content Solutions Segment [Member] | Image Enhancement and Maintenance Services [Member]
Disaggregation of Revenue [Line Items]
Revenues		32,101	20,970
Content Solutions Segment [Member] | Image Enhancement and Maintenance Services [Member] | Film Remastering And Distribution [Member]
Disaggregation of Revenue [Line Items]
Revenues		30,073	19,564
Content Solutions Segment [Member] | Image Enhancement and Maintenance Services [Member] | Other Content Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenues		2,028	1,406
Content Solutions Segment [Member] | Technology Rentals [Member]
Disaggregation of Revenue [Line Items]
Revenues			18
Content Solutions Segment [Member] | Technology Rentals [Member] | Other Content Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenues			18
Technology Products and Services Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues	[1]	51,667	37,863
Technology Products and Services Segment [Member] | System Sales [Member]
Disaggregation of Revenue [Line Items]
Revenues		16,119	7,973
Technology Products and Services Segment [Member] | System Rentals [Member]
Disaggregation of Revenue [Line Items]
Revenues		20,058	12,643
Technology Products and Services Segment [Member] | Maintenance [Member]
Disaggregation of Revenue [Line Items]
Revenues		13,551	14,942
Technology Products and Services Segment [Member] | Technology Sales [Member]
Disaggregation of Revenue [Line Items]
Revenues		16,119	7,973
Technology Products and Services Segment [Member] | Technology Sales [Member] | System Sales [Member]
Disaggregation of Revenue [Line Items]
Revenues		16,119	7,973
Technology Products and Services Segment [Member] | Image Enhancement and Maintenance Services [Member]
Disaggregation of Revenue [Line Items]
Revenues		13,551	14,942
Technology Products and Services Segment [Member] | Image Enhancement and Maintenance Services [Member] | Maintenance [Member]
Disaggregation of Revenue [Line Items]
Revenues		13,551	14,942
Technology Products and Services Segment [Member] | Technology Rentals [Member]
Disaggregation of Revenue [Line Items]
Revenues		20,058	12,643
Technology Products and Services Segment [Member] | Technology Rentals [Member] | System Rentals [Member]
Disaggregation of Revenue [Line Items]
Revenues		20,058	12,643
Technology Products and Services Segment [Member] | Finance Income [Member]
Disaggregation of Revenue [Line Items]
Revenues		1,939	2,305
Content Solutions Segment Technology Products and Services Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues		83,768	58,851
Content Solutions Segment Technology Products and Services Segment [Member] | Technology Sales [Member]
Disaggregation of Revenue [Line Items]
Revenues		16,119	7,973
Content Solutions Segment Technology Products and Services Segment [Member] | Image Enhancement and Maintenance Services [Member]
Disaggregation of Revenue [Line Items]
Revenues		45,652	35,912
Content Solutions Segment Technology Products and Services Segment [Member] | Technology Rentals [Member]
Disaggregation of Revenue [Line Items]
Revenues		20,058	12,661
Content Solutions Segment Technology Products and Services Segment [Member] | Finance Income [Member]
Disaggregation of Revenue [Line Items]
Revenues		1,939	2,305
All Other Segment [Member]
Disaggregation of Revenue [Line Items]
Revenues		3,178	1,185
All Other Segment [Member] | Technology Sales [Member]
Disaggregation of Revenue [Line Items]
Revenues		1,703	1,003
All Other Segment [Member] | Image Enhancement and Maintenance Services [Member]
Disaggregation of Revenue [Line Items]
Revenues		$ 1,475	$ 182
[1] The Company’s largest customer represents 9 % of total Revenues for the three months ended March 31, 2023 (2022 — 11 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of March 31, 2023 and December 31, 2022 .

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenues earned	$ 86,946	$ 60,036
Revenues earned from leasing arrangements	22,400		$ 13,600
Maintenance Services [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue Remaining Performance Obligation	22,200		21,000
Revenues earned	47,127	36,094
Technology Sales [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenues earned	17,822	8,976
Revenues earned from leasing arrangements	2,300		1,000
Technology Sales [Member] | Variable Consideration Receivables [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenues earned	5,600		400
Technology Rentals [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenues earned	20,058	$ 12,661
Revenues earned from leasing arrangements	$ 20,100		$ 12,600

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	3 Months Ended
	Mar. 31, 2023
Segment Reporting (Textual) [Abstract]
Disclosure on geographic areas, description of revenue from external customers	United States and Greater China each comprises greater than 10%

Segment Reporting - Segment Rep

Segment Reporting - Segment Reporting Information by Reportable Segment (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Revenues
Revenue	[1]	$ 86,946	$ 60,036
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		50,051	31,771
Content Solutions
Revenues
Revenue	[1]	32,101	20,988
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		17,995	12,625
Technology Products and Services
Revenues
Revenue	[1]	51,667	37,863
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		29,891	18,416
Sub-total for Reportable Segments
Revenues
Revenue	[1]	83,768	58,851
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)		47,886	31,041
All Other [Member]
Revenues
Revenue	[1],[2]	3,178	1,185
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	$ 2,165	$ 730
[1] The Company’s largest customer represents 9 % of total Revenues for the three months ended March 31, 2023 (2022 — 11 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of March 31, 2023 and December 31, 2022 . All Other includes the results from IMAX Enhanced , SSIMWAVE, and other ancillary activities.

Segment Reporting - Segment R_2

Segment Reporting - Segment Reporting Information by Reportable Segment (Parenthetical) (Details)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Percentage of total revenues represented by largest customer	9%	11%

Segment Reporting - Summary of

Segment Reporting - Summary of Revenues By Geographic Area (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total	[1]	$ 86,946	$ 60,036
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		26,753	19,067
Greater China [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		26,566	21,476
Asia (excluding China) [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		10,652	5,767
Western Europe [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		10,168	7,061
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		7,196	1,772
Latin America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		1,603	1,886
Russia/the CIS & Ukraine [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total	[2]	135	1,010
Rest of the World [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		$ 3,873	$ 1,997
[1] The Company’s largest customer represents 9 % of total Revenues for the three months ended March 31, 2023 (2022 — 11 % ). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of March 31, 2023 and December 31, 2022 . In addition to Russia, the Company has IMAX Systems in the Commonwealth of Independent States ( “CIS”) which are Azerbaijan, Belarus, Kazakhstan, and Kyrgyzstan. Commencing in March 2022, in response to the ongoing conflict between Russia and Ukraine and resulting sanctions, the Company suspended its operations in Russia and Belarus. As of March 31, 2023, the IMAX network includes 54 systems in Russia, eight systems in Ukraine, and one system in Belarus.

Employees Pension and Postret_2

Employees Pension and Postretirement Benefits - Additional Information (Details) - USD ($)		3 Months Ended
	Sep. 19, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Deferred Compensation Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Deferred compensation plan description		The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if the executive incurred a separation from service from the Company (as defined therein).
Deferred Compensation Plan [Member] | Accrued and Other Liabilities [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit obligation recorded		$ 3,900,000		$ 3,900,000
Deferred Compensation Plan [Member] | Prepaid Expenses [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Company-owned life insurance		$ 3,400,000		3,400,000
Richard L. Gelfond [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit payable	$ 20,300,000
SERP Benefits [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Defined benefit pension plan		The Company has an unfunded defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP”), covering its CEO, Richard L.
Benefit Obligation		$ 17,500,000		17,300,000
Companies contribution and expenses during the remainder of 2023		0
SERP Benefits [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Interest costs		200,000	$ 100,000
Expected interest costs in the remainder of the year		$ 600,000
Defined Contribution Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Defined contribution pension plans for employees		The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums.
Maximum percentage of base salary contributed to Defined Contribution Pension Plan by Company		5%
Canadian Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Contribution and recorded expense		$ 300,000	300,000
Us Internal Revenue Code [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Contribution and recorded expense		300,000	300,000
Postretirement Benefits Executives [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit Obligation		500,000		500,000
Postretirement Benefits Executives [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Maximum amount of Postretirement benefit recorded expense		100,000	100,000
Postretirement Benefits Canadian Employees [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit Obligation		900,000		$ 1,000,000
Postretirement Benefits Canadian Employees [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Maximum amount of Postretirement benefit recorded expense		$ 100,000	$ 100,000

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) $ in Thousands, ¥ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) Country	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CNY (¥)	Dec. 31, 2022 USD ($)	Jan. 10, 2022 USD ($)	Jan. 10, 2022 CNY (¥)
Financial Instruments (Textual) [Abstract]
Cash and cash equivalents	$ 99,246			$ 97,401
Cash held outside of Canada	$ 83,600			79,700
Number of countries that generate box office | Country	87
Foreign Exchange contract settlement date range	settlement dates throughout 2023 and 2024
Estimated loss to be reclassified to earnings within the next twelve months	$ (200)
Investment in equity securities	1,050			1,035
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]
Financial Instruments (Textual) [Abstract]
Notional value	34,400			24,700
Preferred Stock [Member] | Other Assets [Member]
Financial Instruments (Textual) [Abstract]
Investment in equity securities - cost	1,000			1,000
Wanda Film (Horgos) Co. Ltd [Member]
Financial Instruments (Textual) [Abstract]
Investments in film					$ 4,700	¥ 30
Investment in film impairment		$ 4,500	¥ 30
China [Member]
Financial Instruments (Textual) [Abstract]
Cash held/undistributed earnings	$ 47,200			$ 43,700

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands		Mar. 31, 2023	Dec. 31, 2022
Other Financial Instrument
Cash and cash equivalents		$ 99,246	$ 97,401
Net investment in sales-type leases		30,762	28,332
Foreign exchange contracts forwards		(176)	(649)
Credit Facility borrowings		(31,025)	(36,111)
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	99,246	97,401
Equity securities	[2]	1,050	1,035
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Net financed sales receivables	[3]	100,425	101,052
Net investment in sales-type leases	[3]	30,762	28,332
Equity securities	[1]	1,000	1,000
COLI	[4]	3,428	3,398
Convertible Notes	[5]	(230,000)	(230,000)
Carrying Amount, Fair Value Disclosure [Member] | Wells Fargo Credit Facility [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(20,000)	(25,000)
Carrying Amount, Fair Value Disclosure [Member] | Bank of China Facility [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(379)	(374)
Carrying Amount, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts forwards	[2]	(176)	(649)
Carrying Amount, Fair Value Disclosure [Member] | HSBC China Facility [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(12,165)	(12,496)
Carrying Amount, Fair Value Disclosure [Member] | Federal Economic Development Loan [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Credit Facility borrowings	[3]	(2,043)	(1,782)
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	99,246	97,401
Equity securities	[2]	1,050	1,035
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Net financed sales receivables	[3]	96,801	100,059
Net investment in sales-type leases	[3]	30,716	27,972
Equity securities	[1]	1,000	1,000
COLI	[4]	3,428	3,398
Convertible Notes	[5]	(218,210)	(196,717)
Estimate of Fair Value, Fair Value Disclosure [Member] | Wells Fargo Credit Facility [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(20,000)	(25,000)
Estimate of Fair Value, Fair Value Disclosure [Member] | Bank of China Facility [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(379)	(374)
Estimate of Fair Value, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts forwards	[2]	(176)	(649)
Estimate of Fair Value, Fair Value Disclosure [Member] | HSBC China Facility [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Credit Facility borrowings	[1]	(12,165)	(12,496)
Estimate of Fair Value, Fair Value Disclosure [Member] | Federal Economic Development Loan [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Credit Facility borrowings	[3]	$ (2,043)	$ (1,782)
[1] Recorded at cost, which approximates fair value. Fair value is determined using quoted prices in active markets. Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. Measured at cash surrender value, which approximates fair value. Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data.

Financial Instruments - Fair _2

Financial Instruments - Fair Value of Foreign Exchange Contracts (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Derivatives Fair Value [Line Items]
Foreign exchange contracts - designated forwards	$ (176)	$ (649)
Other Assets [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign currency derivatives	193	50
Accrued and other liabilities [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Liability, Fair Value	$ (369)	$ (699)

Financial Instruments - Derivat

Financial Instruments - Derivatives in Foreign Currency Hedging Relationships (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Derivative Instruments Gain Loss [Line Items]
Derivative (Loss) Gain Recognized in OCI (Effective Portion)	$ 134	$ 315
Location of Derivative (Loss) Gain Reclassified from AOCI into Income (Effective Portion)	$ (339)	$ (29)
Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, General and Administrative Expense	Selling, General and Administrative Expense
Fair Value Hedging [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative (Loss) Gain Recognized in OCI (Effective Portion)	$ 134	$ 315

Executive Transition Costs - Ad

Executive Transition Costs - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended
	Mar. 13, 2023	Mar. 31, 2023
Executive Transition Costs [Abstract]
Executive transition costs effective date	Apr. 30, 2023
Executive transition costs		$ 1.4
Severance costs		1.6
Compensation from ongoing consulting services		0.8
Reversal of previously recognized share-based compensation costs		$ 1

Non-Controlling Interests - Add

Non-Controlling Interests - Additional Information (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2014 USD ($) Film	Dec. 31, 2022 USD ($)
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interests	$ 69,090			$ 65,691
Net income attributable to non-controlling interests	2,669	$ 1,659
Investment in film assets	$ 3,884	5,107
IMAX China Noncontrolling Interest
Redeemable Noncontrolling Interest [Line Items]
Minority Interest Ownership Percentage By Company	71.63%			71.73%
IMAX China
Redeemable Noncontrolling Interest [Line Items]
Non-controlling interests	$ 69,100			$ 65,700
Net income attributable to non-controlling interests	2,700	1,700
Other Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Net income attributable to non-controlling interests	$ 9	$ 3
Non-controlling interest description	The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company has contributed $9.0 million to the Original Film Fund since 2014 and has reached its maximum contribution.
Number of expected original films | Film			10
Investment in film assets	$ 22,300
Other Noncontrolling Interest [Member] | Third Party [Member]
Redeemable Noncontrolling Interest [Line Items]
Film fund committed capital contribution			$ 25,000
Other Noncontrolling Interest [Member] | IMAX [Member]
Redeemable Noncontrolling Interest [Line Items]
Film fund contributions paid	$ 9,000

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary of Movement of the Non-controlling Interest in Temporary Equity Related to Original Film Fund (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Non-controlling Interests
Net (loss) income	$ 2,669	$ 1,659
Other Noncontrolling Interest [Member]
Non-controlling Interests
Beginning Balance	722	758
Net (loss) income	9	3
Ending Balance	$ 731	$ 761